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ABSTRACT: A novel molecular scaﬀold has been synthesized, and its incorporation into new analogues of biologically active
molecules across multiple target classes will be discussed. In these studies, we have shown use of the tricyclic scaﬀold to
synthesize potent inhibitors of the serine peptidase DPP-4, antagonists of the CCR5 receptor, and highly potent and selective
PI3K δ isoform inhibitors. We also describe the predicted physicochemical properties of the resulting inhibitors and conclude
that the tractable molecular scaﬀold could have potential application in future drug discovery programs.
■ INTRODUCTION
The search for new molecular scaﬀolds, amenable to expansion
by parallel synthesis techniques, is an important challenge for
synthetic medicinal chemists.1 From our ongoing studies,2−4
into designing such scaﬀolds,5−8 we were drawn to the
possibility of generating a series of readily functionalized
compounds with well-deﬁned conformations that provide
points of diversity expansion for parallel substitution methods.
Central to our scaﬀold design strategy was the growing
evidence that nitrogen containing saturated heterocycles, fused
to substituted heterocyclic rings, are present in many druglike
molecules.9−12 In our design strategy, we wanted to combine
this growing privileged motif within a tricyclic ring system
containing a substituted 1,2,4-triazole ring. This would allow us
to examine geometric isomerism (cis- and trans-ring fusion), the
dihedral angle of the ring junction, and the inﬂuence of
absolute chirality on biological activity. We therefore
considered that the substituted tricyclic ring systems would
be ideal candidates to synthesize and evaluate across multiple
biological targets (Figure 1).
In order to assess the utility of the tricyclic ring system as a
new privileged scaﬀold, we were drawn to the exciting
possibility of substituting the tricyclic scaﬀold into known
biologically active compounds to compare both the resulting
pharmacological activity and their predicted physicochemical
parameters. From the outset of the project, we were interested
in designing a novel molecular entity that, when appropriately
functionalized, would possess potent activity and robust
structure activity relationships (SARs) without being promis-
cuous.13 In addition, we wanted the new compounds to be
“druglike” with respect to their predicted physicochemical
properties.1,14−16 In order to test our hypothesis, we examined
drug case histories where X-ray structural information was
available to allow molecular docking experiments to guide our
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design strategies. As an outcome, we chose to incorporate the
scaﬀold into three distinct series of compounds targeting; a
serine protease (dipeptidyl peptidase-4, DPP-4), a G protein-
coupled receptor (CCR5 receptor antagonist), and a kinase
inhibitor (phosphoinositide 3-kinase, PI3K δ). We report here
our initial ﬁndings in this area of privileged scaﬀold design,
demonstrating potent cross-target biological activity of the
resulting functionalized compounds combined with excellent
predicted physicochemical properties.
■ RESULTS AND DISCUSSION
We recently communicated the synthesis and evaluation of new
DPP-4 inhibitors based on the tricyclic scaﬀold,17 and we now
report further structure activity relationships (SARs) of this
interesting new class of potent DPP-4 inhibitors, demonstrating
the utility for incorporation into druglike molecules (Figure 2).
Type-2 diabetes is a chronic disease, characterized by
elevated blood sugar levels, leading to severe vascular
complications and an increased mortality risk, and it is now
well recognized that inhibition of the widely distributed serine
protease dipeptidyl peptidase-4 (DPP-4) is a clinically validated
target for antidiabetic therapy.18 Sitagliptin was the ﬁrst
approved DPP-4 inhibitor launched by Merck in 2006,19 and
this was followed recently by omarigliptin,20 a once weekly
treatment for type-2 diabetes. Most recently, several series of
structurally diverse DPP-4 inhibitors have been communicated
demonstrating that the search for new compounds is still an
important goal for both pharmaceutical companies and
academic groups (Figure 3).21−23
We previously demonstrated that cis-fused diastereoisomers
(1, 2) were more potent inhibitors than the corresponding
trans-fused diastereoisomers (3, 4). A preference was observed
Figure 1. Molecular scaﬀolds amenable to further substitution. R1 and R2 are points of diversity expansion, X = (−CH2)n, where n = 0 to 2. Φ = the
dihedral angle between the piperidine and substituted 1,2,4-triazole.
Figure 2. DPP-4 inhibitors (1−4), existing as a 1:1 mixture of either cis- or trans-diastereoisomers.
Figure 3. Selection of approved and late stage DPP-4 inhibitors.
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for one of the resolved cis-diastereoisomers, although at the
time of initial disclosure we could not determine the absolute
chirality of the cis- eutomer (Table 1).
To determine the absolute stereochemistry of the resolved
diastereoisomers (1 and 2), we embarked on a diastereomeric
synthesis, as we were unable to obtain crystals of suﬃcient
quality for single crystal X-ray structural analysis. Catalano et al.
recently published24 the stereoselective synthesis of 1-
substituted cyclic ketone 7 using the stereoselective reduction
of imine 6 generated from (S)-1-(4-methoxyphenyl)ethan-1-
amine and δ keto ester 5 (Scheme 1).
Following literature precedent, we attempted to generate
imine 9 from reaction of (S)-1-(4-methoxyphenyl)ethan-1-
amine and δ keto ester 8. However, we were unable to generate
the resulting imine even after heating under Dean−Stark
conditions for several days. We therefore opted for the more
routine reductive amination reaction stirring (S)-1-(4-
methoxyphenyl)ethan-1-amine and δ keto ester 8 in 1,2-
dichlorethane in the presence of sodium triacetoxy borohy-
dride.25 From the literature precedent, we predicted that the
reductive amination using (S)-1-(4-methoxyphenyl) ethan-1-
amine would generate diastereoisomer 2, which had previously
been predicted through molecular docking to be the less-active
diastereoisomer.17,26 The reductive amination reaction pro-
ceeded to aﬀord 10 in 20% yield. Catalytic transfer hydro-
genation removed the 4-methoxybenzyl group, aﬀording the
cyclized bicyclic lactam 11, as a separable 5:1 mixture of cis- to
trans-isomers. The cis-fused isomer 11 was converted to
thiolactam 12 through treatment with Lawesson’s reagent.
The thiolactam 12 was converted into the corresponding
tricyclic triazole 13 by reﬂuxing in toluene with 2,2,2-
triﬂuoroacetohydrazide. The carbamate protecting group was
removed to aﬀord the key molecular scaﬀold 14, which was
reacted with (R)-3-((tert-butoxycarbonyl)amino)-4-(2,4,5-
triﬂuorophenyl)butanoic acid to generate 2, after removal of
the protecting group (Scheme 2).
The ﬁnal product (containing a mixture of 1 and 2) was
analyzed by chiral HPLC, which showed two isomers: 2 (93%)
and 1 (7%). From the literature precedent, we concluded that
the stereoselective synthesis had generated the less biologically
active diastereoisomer (Figure 4), thus demonstrating that the
eutomer was most likely isomer 1? However, further detailed
work needs to be undertaken to demonstrate the precedent-
based assignment of stereochemistry, and this work will be
reported in due course.
To understand the observed diﬀerences seen in DPP-4
inhibitory activity for the isomers, docking studies were carried
out with the crystal structure of sitagliptin in DPP-4 (PDB code
1X70).19,26 It has been known that the primary amine present
in sitagliptin has strong ionic interactions with E205, E206, and
Y662 and π-stacking with Y662all of which have been shown to
be conserved within the compounds (1, 2). In addition,
sitagliptin has further electrostatic and van der Waals
interactions with S207, F357, and R358 in the S2 pocket and a
further hydrogen bonding interaction, through a water
molecule, to Y547 (Figure 5a).
19 From the molecular docking
experiments, it was shown that the more active cis-fused
diastereoisomer 1 maintained the strong interactions with S207,
F357, and R358 but had suboptimal hydrogen bonding
interaction with Y547 (Figure 5b). This might explain the
small reduction in activity of 1 when compared to sitagliptin.
Similarly, 2 was shown to lack the hydrogen bonding
interactions with Y547, S207, and R358 (Figure 4c), suggesting a
likely rationale for the observed diﬀerences seen in DPP-4
inhibitory activity between 1 and 2.
Due to the convergent synthesis, it was possible to rapidly
synthesize a range of analogs (40−47) which were prepared in
a similar fashion to those already reported (1−4) (Scheme 3).
The known bicyclic thioamides (15, 16)17,27 were reacted
with a range of substituted acyl hydrazides (R1CONHNH2) to
give tricyclic triazoles (17−23), which were deprotected to the
corresponding N−H piperidines (24−31) in reﬂuxing KOH in
aqueous ethanol. The resulting piperidines (24−31) were
reacted with (R)-3-((tert-butoxycarbonyl)amino)-4-(2,4,5-
triﬂuorophenyl)butanoic acid to give, after deprotection, the
corresponding analogs (40−47).
Table 1. DPP-4 Inhibitory Activitya
Compoundb cis- or trans- DPP-4 IC50 [nM]
1 cis- 28 ± 1c
2 cis- 70 ± 2c
3 trans- 145 ± 5c
4 trans- 537 ± 23c
aSitagliptin IC50 22 ± 2 nM.
bSingle diastereomer with unknown
absolute conﬁguration. cPotency is given as IC50 values (n = 2).
Scheme 1. Catalano et al. Synthetic Procedurea
aReagents and conditions: (a) (1S)-1-[4-(methyloxy)phenyl]ethanamine, p-TosOH, toluene, Dean−Stark, 4 h.; (b) NaBH(OAc)3, 1,2-DCE, 16 h
(61%).
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Through substituting the group R1, an interesting structure
activity relationship (SAR) was revealed within this class of new
DPP-4 inhibitors (Table 2).
Once more, the cis-fused diasteroisomer 41 proved more
active that the trans-fused diastereisomer 47. It is encouraging
to note that R1 substitution, with either small alkyl groups (40,
41) or heterocycles (44−46), gave compounds with high DPP-
4 inhibitory activity, while larger groups (42, 43) led to a
reduction in DPP-4 inhibitory activity. This suggested a steric
requirement for the R1 substituent within the DPP-4 active site.
This is most notable when considering the 3-ethoxypyrid-2-yl
43 and 2-pyridyl 44 analogues, which shows that an increase in
Scheme 2. Synthesis of 2 Derived from (S)-1-(4-Methoxyphenyl)ethan-1-amine and δ Keto Ester 8a
aReagents and conditions: (a) (S)-1-(4-methoxyphenyl)ethan-1-amine, sodium triacetoxy borohydride, 1,2-dichloromethane rt 20 h; (b) ammonium
formate, ethanol, 10% Pd on C, 70 °C, 10 h; (c) Lawesson’s reagent (0.5 equiv), 120 °C, toluene, 30 min; (d) CF3CONHNH2, toluene 120 °C, 20
h; (e) KOH, water/ethanol, 120 °C, 20 h; (f) (i) EDCI, HOBt, DMF, (R)-3-((tert-butoxycarbonyl)amino)-4-(2,4,5-triﬂuorophenyl)butanoic acid, rt,
20 h, (ii) 4 N HCl in 1,4-dioxane.
Figure 4. (a) Analytical chiral HPLC analysis of the ﬁnal mixture of products, containing 2 (93%) and 1 (7%); (b) sample spiked with the previously
separated, eutomer 1. Phenomenex LC Lux 5u Amylose-2 packed column (250 × 4.6 mm) at a ﬂow rate of 1.5 mL/min, using 70% hexane: 30%
ethanol supplemented with 0.2% diethylamine over 30 min.
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size results in a 3-fold reduction in DPP-4 inhibitory activity.
This can be rationalized through considering the docking of 43,
which showed a possible steric clash of the ethoxyl group with
S209 in the active site (Figure 6).
26
One of our success criteria was that the resulting compounds
should be lead-like with respect to their physicochemical
properties.15,16,28 As a metric to demonstrate lead-likeness, we
chose to evaluate the lipophilic ligand eﬃciency (LIPE)11,29−31
of our most potent analogues and compare them to sitagliptin
(Table 3).
It was gratifying to note that 40 displayed very good
predicted druglike characteristics (LIPE 6.9), comparing
favorably to sitagliptin. Further analysis showed 40 to have a
favorable topological polar surface area (TPSA)33 value of 77
Å2 and high predicted solubility in water (calculated solubility
at pH 7.4: 5.39 mg/mL, sitagliptin: 3.20 mg/mL).32
Having demonstrated that the molecular scaﬀold was capable
of generating compounds with excellent biological activity
balanced with good calculated lead-like physicochemical
properties against one target class, we chose to look at
designing a series of GPCR receptor antagonists. In our second
case study, we chose the chemokine receptor CCR5 as the
biological target, as we were drawn to the structural similarity
between the tricyclic ring system and the corresponding group
present in the CCR5 receptor antagonist, maraviroc (Figure 7).
The CCR5 receptor is a chemokine receptor, which is
located on the cell surface of T cells and can bind speciﬁc
peptide ligands called chemokines and belong to a large family
of the seven transmembrane GPCRs. The human CCR5
receptor itself is a 352 amino acid protein and consists of seven
transmembrane spanning helices connected through three
extracellular loops (ECL1, ECL2, and ECL3), three intra-
cellular loops, an extracellular N-terminus, and an intracellular
C-terminus and N-terminus functionality. The extracellular
loops and transmembrane helices are responsible for binding
ligands, and the intracellular regions are responsible for signal
transduction. The activation of the chemokine receptor CCR5
through its binding of endogenously expressed chemokines
(macrophage inﬂammatory proteins MIP-1α and MIP-1β as
well as “regulated on activation, normal T cell expressed, and
secreted” RANTES) can cause typical cellular responses,
including inhibition of cAMP production or stimulation of
intracellular Ca2+.34 CCR5 is a coreceptor for HIV entry into T
cells, and maraviroc is the only marketed CCR5 receptor
antagonist for R5 HIV therapy to date.35,36
While our chemical design appears a rational “fast-follower”
process, we were concerned that the tropane ring present in
maraviroc had been shown to give a 40-fold increase in aﬃnity
compared to the piperidine analogue.37 In addition, the triazole
group in maraviroc adopts a conformation where it is
orthogonal to the tropane ring, whereas in our proposed
analogue the triazole group would be occupying a diﬀerent
spatial conﬁguration. As a consequence of these considerations,
we decided to generate a receptor model based on the reported
maraviroc-bound X-ray crystal structure of CCR5 and examined
the overlay and key receptor interactions of our proposed
analogues to that of maraviroc (Figure 8).26 In the molecular
docking, it was shown that a very good overlay to maraviroc
was observed with the cis-fused diastereoisomer 48. In addition,
key hydrogen bonding interactions were seen to T195, T259, Y251,
E283, and Y37 and strong face-to-face interaction with W86-
interactions was reported for maraviroc.38
In light of the positive docking results, we proceeded to
embark on a synthesis of the maraviroc analogues, using an
analogous route to the previously reported synthesis (Scheme
4). Unfortunately, the ﬁnal compounds could not be separated
into single diastereoisomers, and so the compounds were
screened as either a mixture or separated cis- or trans-
diastereoisomers (48−49).
Benzyl (S)-(3-oxo-1-phenylpropyl)carbamate39 was reacted
with piperidines (24, 50) under reductive amination con-
ditions25 to give Cbz-protected intermediates (51a−b) which
were deprotected and acylated with 4,4-diﬂuorocyclohexane-1-
carboxylic acid to generate the maraviroc analogues (48, 49) in
good overall yield.
RANTES was chosen as the agonist in our biological
evaluation, as receptor agonism with MIP-1α was shown to be
less reproducible in our hands. This biological screen was
carried out using the Ca2+ signaling assay by testing the ability
of a single concentration of antagonist [30 nM (48) or 1 μM
(49), ﬁnal concentration] to shift agonist (RANTES)
concentration response curves, and the estimated aﬃnity values
(pKD)
40 are summarized in Table 4.
It is interesting to note that, even though the lipophilic
tropane interaction present in maraviroc was absent in 48, a
very good level of CCR5 receptor antagonism was observed.
Figure 5. (a) Sitagliptin (magenta) in DPP-4 (PDB code 1X70); (b)
eutomer 1 docked into DPP-4; (c) diastereoisomer 2 docked into
DPP-4.26
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Importantly, a reduction in calculated lipophilicity and
molecular weight might lead to an improvement in ADME
properties? However, further research is required to demon-
strate that the calculated druglike properties may lead to an
improved over all proﬁle.
Having demonstrated that the new molecular scaﬀold was
capable of generating compounds with excellent biological
activity and activity against two target classes, we chose to look
at utilizing the scaﬀold into the design of a series of kinase
inhibitors. In this approach, we wanted to use the molecular
scaﬀold to function as a key molecular recognition group to
increase kinase activity and also ﬁne-tune kinase isoform
selectivity. In this respect, we were drawn to the exciting
possibility of designing a set of potent and selective
phosphoinositol-3 kinase δ isoform inhibitors, an area of
interest from our University of Nottingham and GlaxoSmithK-
line research teaching collaboration.41
Phosphoinositol-3 kinase (PI3K) signaling plays a central
role in cellular functioning, including growth, proliferation,
survival, or migration. It therefore has a pivotal role in diseases
such as those related to the respiratory tract, e.g. asthma42 and
cancer.43 These lipid kinases catalyze phosphorylation, which
leads to the production of phosphatidylinositol (PI(3,4,5)P3)
through the isoforms α, β, γ, and δ. (PI(3,4,5)P3) is involved in
the signaling of kinase Akt (protein kinase B), which is a
serine/threonine protease involved in cell growth, survival,
proliferation, and angiogenesis. Phosphoinositol (3,4,5)-tri-
sphosphate (PIP3) is an important intracellular second
messenger, whose biological action occurs through stimulating
increase of the intracellular calcium ion concentration. The PI3
Scheme 3. Synthetic Route to Compounds 40−47a
aReagents and conditions: (a) R1CONHNH2, toluene 120 °C, 20 h. 31−75% yields. (b) KOH, water/ethanol, 120 °C, 20 h. 54−87% yields. (c)
EDCI, HOBt, DMF, (R)-3-((tert-butoxycarbonyl)amino)-4-(2,4,5-triﬂuorophenyl)butanoic acid rt, 20 h, 45−98% yields. (d) 4 N HCl in dioxane,
95−100% yields. Compounds 40−47 exist as a 1:1 racemic mixture of either cis- or trans-diastereoisomers.
Table 2. DPP-4 Inhibitory Activitya
Compoundb cis- or trans- R1 DPP-4 IC50 [nM]
c
40 cis- CH3 28 ± 0.9
41 cis- isopropyl 31.8 ± 0.8
42 cis- benzyl 123.3 ± 6.8
43 cis- 6-ethoxypyrid-2-yl 139 ± 4.1
44 cis- 2-pyridyl 43.4 ± 1.3
45 cis- 2-pyrazinyl 60.0 ± 2.1
46 cis- 4-(2-methyl)thiazolyl 50.2 ± 1.0
47 trans- isopropyl 151.7 ± 9.4
aSitagliptin IC50 = 22 ± 2 nM (n = 16).
b1:1 mixture of
diastereoisomers. cPotency is given as IC50 values (n = 2).
Figure 6. Proposed binding of 43 in the DPP-4 active site (PDB code
1X70) overlaid on sitagliptin (cyan), showing a steric clash with S209.
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Table 3. Calculated Physicochemical Parameters of
Sitagliptin and Compounds 1, 40, and 41
Compound pIC50 cLogP
a cLogDa MWt LIPEb
Sitagliptin 7.66 1.26 −0.01 407.3 6.4
1 7.56 1.84 0.44 461.5 5.7
40 7.56 0.7 −0.07 407.5 6.9
41 7.49 1.95 0.55 435.5 5.6
aCalculated using instant JChem.32 bLIPE = pIC50 − cLogP.
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Figure 7. Proposed new CCR5 receptor antagonists (48 and 49) based on maraviroc.
Figure 8. Maraviroc (magenta) and cis-fused diastereoisomer 48 (green) docked into the CCR5 receptor model (generated from PDB code 4MBS).
Illustrated H-bond and lipophilic interactions shown with CCR5 amino acid residues. Close up showing the overlay of the tropane and 1,2,4-triazole
groups.
Scheme 4. Synthetic Route to Compounds 48−49a
aReagents and conditions: (a) NaBH(OAc)3, DCE, rt, 20 h. (b) (i) Pd/C, MeOH, hydrogen, rt, 20 h; (ii) 4,4-diﬂuorocyclohexane-1-carboxylic acid,
HATU, DIPEA, DMF, rt, 20 h. n.b. yields of ﬁnal products are quoted after reverse phase HPLC puriﬁcation.
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kinase family can be divided into three diﬀerent classes
depending on their domain structure. The main focus in
current research is on the class 1 PI3Ks, which consist of four
members. The majority of research is concentrated on the class
1A subunit isoforms PI3K α, PI3K β, and PI3K δ, and
furthermore the class 1B subunit PI3K γ. Due to their
fundamental roles, the design of selective inhibitors is
important to consider, as nonselective compounds could result
in toxicity. As PI3K δ expression is limited to leukocytes, its
inhibition has potential for the treatment of respiratory
diseases42 and leukemia.44,45 The reduction of response in
PI3K δ knock in (KI) mice and animals was seen after
treatment with a PI3 δ speciﬁc inhibitor, which is demonstrated
by reduced clonal expansion of CD4 cells and diminished
pathology in asthma models.46 The inactivation of PI3K δ also
aﬀects mast cell function, which plays an important role in
allergic responses and asthma.
In this case study, we considered pictilisib,47 a pan PI3K
inhibitor, as the chemical starting point, as the X-ray crystal
structure was available.48 In addition, 52 was recently reported
as a more selective PI3K δ inhibitor [PI3K α (340-fold), PI3K β
(200-fold), PI3K γ (410-fold)], suggesting that PI3K δ isoform
selectivity could be achieved within the thienyl pyrimidine class
of PI3K inhibitors.49 Our plan was to investigate the role for the
incorporation of the molecular scaﬀold to synthesize a series of
potent and selective PI3K δ inhibitors (Figure 9).
Modest PI3K δ isoform selectivity has been reported though
an edge to face interaction of the thienyl pyrimidine with
W760the so-called tryptophan shelf interaction.49 In addition,
it is known that, even though there is good homology between
the PI3K isoforms, an important residue change exists between
the four isoforms that might also aid δ isoform selectivity. An
overlay of the available crystal structures reveals a potential key
π−cation interaction present in the structures of the α (K750), β
(K771), and γ (K771) isoforms with W760 (δ-numbering) that is
not present in PI3K δ (T750). This led us to the exciting
possibility that our inhibitors might be able to form an extra van
der Waal π−π face to face interaction with W760, an interaction
occluded in the case of the other isoforms (Figure 10).
Furthermore, it has been reported that selectivity for PI3K δ
can be achieved in part due to the eﬀect of the aﬃnity pocket
group R2, with R2 = 4-substituted indole giving rise to good
PI3K δ isoform selectivity.49 We therefore decided to use a
small 3D matrix-based approach (18 compounds) to evaluate
the potency and selectivity proﬁles of substituting groups R1,
R2, and R3 (Figure 11). In addition, we included the open chain
analogues (62−67) to evaluate the role of the tricyclic ring
system on potency and selectivity.
The synthesis of the compounds (62−79) was accomplished
through a two-step procedure. The acyclic intermediates (53
and 54) were prepared by the high-yielding 1,2,4-triazole
synthesis method as outlined by Stocks (Scheme 5).4
The six substituted piperidines (groups R1 in Figure 11) were
reacted with aldehyde 5547 using picoline borane51 as the
reducing agent in 10% acetic acid in methanol to generate the
key intermediates (56−61) that were then subjected to
Suzuki−Miyaura cross-coupling reactions52,53 to aﬀord com-
pounds (62−79) in high yield (Scheme 6).
Table 4. pKD and Key Predicted Physicochemical Values of
48 and 49 Compared to Maraviroc
Compound pKD
a cLogPb cLogDb MWt LIPE
maraviroc 8.8 ± 0.2 3.6 1.4 514 5.2
48 8.0 ± 0.2 2.1 0.2 472 5.9
49 6.5 ± 0.1 2.1 0.2 472 4.4
aThe estimated aﬃnity value for each antagonist (pKD) was calculated
from the shift of the agonist dose response curve brought about by
addition of a single concentration of antagonist using the Gaddum
equation.Tested n = 6. bCalculated using Instant JChem32
Figure 9. Potent pan PI3K inhibitor pictilisib, δ-selective PI3K inhibitor 52, and proposed inhibitors based on the tricyclic scaﬀold.
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The compounds were screened against PI3K isoforms, and
their biological activities are reported in Table 5.54
It is interesting to note that all the compounds demonstrated
a good degree of isoform selectivity for PI3K δ over PI3K α,
PI3K β, and PI3K γ. However, the following discussion will
concentrate on the PI3K δ/α isoform selectivity (Figure 12).
A plot of PI3K δ potency versus PI3K α potency showed a
general trend that compounds with R2 = 4-substituted indolyl
[e.g., 73 (∼4000-fold), 72, and 78 (∼2000-fold)] were more
PI3K δ isoform selective49 (Figure 13).
It is noteworthy that high PI3K isoform selectivity was also
achieved, where R2 = 4-indazolyl (71, δ/α ∼ 500-fold, δ/β ∼
400-fold, δ/γ ∼ 400-fold), demonstrating that high PI3K δ
isoform potency, and therefore selectivity, could be enhanced
by the methyl-substituted cis-fused tricyclic molecular scaﬀold
over the acyclic scaﬀold (compare 71 with 63), suggesting that
our initial proposal from molecular docking studies for further
interaction of the cis-fused tricyclic scaﬀold with W760 may be
driving the PI3K δ isoform activity and therefore selectivity
independently of the known activity pocket selectivity aﬀorded
by the 4-substituted indole group. Further analysis of the role of
group R1 showed a general trend, with the tricyclic compounds
showing a greater level of activity at PI3K δ than PI3K α when
compared to the acyclic compounds. This is very apparent
when looking at a matched-pair analysis55 between compounds
containing the acyclic scaﬀold (groups A) and the cis-fused
tricyclic containing compounds (groups B)compare 65 with
69, 66 with 68, 63 with 71, 67 with 72, and 64 with 73. (Figure
14). From the analysis, the matched-pairs generally have similar
levels of PI3K α activity, but the inclusion of the cis-fused
tricyclic ring increases the level of PI3K δ activity, with the
largest diﬀerence in PI3K δ activity being observed for the
matched pairs (67 and 72).
A similar proﬁle was observed between compounds
containing the acyclic scaﬀold (groups A) and the trans-fused
tricyclic containing compounds (groups C)compare 65 with
75, 62 with 79, 66 with 74, 63 with 76, 67 with 77, and 64 with
78 (Figure 15).
Further examination of group R1 as a function of PI3K δ/α
selectivity showed that the tricyclic compounds (groups B and
C) give rise to a very good selectivity proﬁle with (72, 73, and
78), showing the optimal balance between very high PI3K δ
activity and selectivity over PI3K α (Figure 16).
Indeed, it is very encouraging to note that compound 73
achieved a very high degree of PI3K δ selectivity over PI3K β
(∼400-fold) and PI3K γ (2000-fold). To test the druglikeness
of the synthesized compounds, the physicochemical properties
of 73 were calculated (PI3K δ (pIC50 = 9.1), MWt 540.7,
cLogP 3.9, clogD 2.5, TPSA 88 Å2, solubility at pH 7.4 in water:
Figure 10. (A) Depiction of the tryptophan shelf and amino acid
changes in PI3K isoforms to occlude binding of the tricyclic scaﬀold
−shown with PI3K α isoformpdb 5DXT.50 (B) Molecular docking
of cis-fused diasteroisomer 73 into PI3K δ (pdb 2WXP48), highlighting
potential face-to-face interaction with the tricyclic scaﬀold. Pictilisib
(magenta) and 73 (green).
Figure 11. 3D-Matrix-based chemistry plan to explore PI3K δ isoform selectivity of the tricyclic molecular scaﬀold.
Scheme 5. Synthesis of Acyclic Analogue Intermediates (53−
54)*
*The intermediates were deprotected with TFA in dichloromethane
immediately prior to the subsequent reaction.
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0.02 mg/mL, solubility category: Low, LIPE = 5.2).32 While the
properties may not be ideal for oral druglikeness, the
compounds may fulﬁll inhalation delivery criteria, where
MWt appears to be less important for successful drug
development.46,56 In addition, the compound may well prove
very useful as a highly selective tool compound to further probe
biological mechanisms for the role of PI3K δ in other
therapies.57−59
Within the three case histories presented, the cis-fused
diastereoisomer of the tricyclic scaﬀold (Figure 1) proved the
most potent diastereoisomer. It is interesting to speculate that a
common molecular recognition motif might be present in each
of the biological targets, and further work is ongoing in our
laboratory to explore this exciting possibility.
Implicit to the design strategy was to generate a series of new
molecular entities that could be readily diversiﬁed by robust
synthetic chemistry. In our considerations, it was important to
ensure that the scaﬀolds contained suﬃcient functionality to
allow hydrogen bonding interaction within diverse biological
systems but also possessed a suﬃcient degree of lipophilicity to
make interactions with lipophilic amino acids within the
binding pockets. In our design phase, we rationalized that the
optimal strategy for obtaining biological interactions in novel
scaﬀolds was to separate the polar groups with hydrogen bond
neutral linking groups and, importantly, to avoid the proximity
of too many polar interactive groups that could lead to
reduction in binding. We therefore suggest the following simple
strategy to consider when generating new molecular scaﬀolds
for high hit rate compound libraries, as well as for use in lead
optimization programs where scaﬀold diversity is required:
• Examine the medicinal chemistry literature and identify
core “over-represented” features in druglike molecules to
Scheme 6. Synthesis of Potential PI3K Inhibitors (62−79)a
aReagents and conditions: (a) picoline borane/10% AcOH in methanol 20 h, yields 30−91%; (b) Na2CO3, EtOH (aq), boronic acid (1.5 equiv),
bis(triphenylphosphine) palladium chloride (0.1 equiv), microwave 120 °C, 30 min, yields 54−97%. Compounds 68−79 exist as a 1:1 racemic
mixture of either cis- or trans- diastereoisomers.
Table 5. Biological Evaluation and Isoform Selectivity for PI3K δ for Compounds 62−79
Isoform potencya,b (pIC50) Isoform selectivity
Example R1 R2 R3 PI3K δ PI3K α PI3K β PI3K γ δ/α δ/β δ/γ
62 A D CH3 8.4 ± 0.0 7.0 ± 0.0 6.8 ± 0.1 6.7 ± 0.1 25 40 50
63 A E CH3 8.0 ± 0.0 6.5 ± 0.1 6.0 ± 0.2 6.0 ± 0.0 32 100 100
64 A F CH3 8.4 ± 0.1 5.7 ± 0.2 6.4 ± 0.0 5.7 ± 0.2 501 100 501
65 A D CF3 8.6 ± 0.2 7.2 ± 0.0 7.0 ± 0.0 6.8 ± 0.0 25 40 63
66 A E CF3 7.7 ± 0.0 6.5 ± 0.1 5.9 ± 0.2 6.1 ± 0.0 16 63 40
67 A F CF3 7.7 ± 0.1 5.4 ± 0.0 6.1 ± 0.2 5.5 ± 0.0 200 40 158
68 B E CF3 8.6 ± 0.0 6.5 ± 0.0 6.4 ± 0.0 6.1 ± 0.0 126 158 316
69 B D CF3 9.2 ± 0.0 7.2 ± 0.0 7.3 ± 0.0 6.8 ± 0.0 100 79 251
70 B D CH3 * * * * * * *
71 B E CH3 8.5 ± 0.4 5.8 ± 0.3 5.9 ± 0.3 5.9 ± 0.2 501 398 398
72 B F CF3 9.1 ± 0.1 5.8 ± 0.1 7.0 ± 0.1 6.2 ± 0.1 1995 126 794
73 B F CH3 9.1 ± 0.0 5.5 ± 0.1 6.5 ± 0.2 5.8 ± 0.0 3981 398 1995
74 C E CF3 8.1 ± 0.0 6.8 ± 0.0 6.2 ± 0.0 6.0 ± 0.0 20 79 126
75 C D CF3 9.0 ± 0.3 7.5 ± 0.1 7.3 ± 0.1 6.7 ± 0.0 32 50 200
76 C E CH3 8.4 ± 0.1 6.8 ± 0.2 6.3 ± 0.1 6.5 ± 0.1 40 126 79
77 C F CF3 8.8 ± 0.2 6.3 ± 0.1 6.8 ± 0.2 6.4 ± 0.2 316 100 251
78 C F CH3 9.0 ± 0.0 5.7 ± 0.1 6.5 ± 0.2 6.1 ± 0.2 1995 316 794
79 C D CH3 9.1 ± 0.4 7.0 ± 0.1 6.9 ± 0.1 6.3 ± 0.3 126 158 631
aPotency against the diﬀerent PI3K isoforms is given as pIC50 values (n = 2).
bThe potency threshold for the PI3K δ assay is ∼ pIC50 9 due to
substrate concentration. *Example 70 proved insoluble in the assay buﬀer for biological testing.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.6b01801
J. Med. Chem. 2017, 60, 1534−1554
1543
enable design mimics with structural diversity, while
maintaining core physicochemical properties.
• Hypothesize new ring systems containing aspects of
these features (i.e., fused/spirocyclic ring systems)
containing a maximum of two points of diversity,
remembering the virtue of rings within medicinal
chemistry design has good precedence60 due to their
higher intrinsic ligand eﬃciency, increased crystallinity,
and reduction in degrees of ﬂexibility (ΔG vs ΔS)
compared to acyclic systems.
• Re-evaluate chemical design to remove overcomplexity
and unwanted functionality to improve synthetic
tractability, including stereocontrol for chiral centers,
and include “simple opportunities” to modify scaﬀolds at
a later stage.61
• Enumerate and proﬁle a small subset of the virtual library
based on physicochemical properties and deselect
scaﬀolds that do not oﬀer compounds with good
physicochemical properties.1
• Generate sets of closely related scaﬀolds with common
capping chemistries to expedite synthesis.
• Complete the library matrix to build SAR and discover
serendipitous synergistic group eﬀects.
■ CONCLUSION
In summary, we have shown the successful synthesis of
promising new druglike compounds as inhibitors of DPP-4,
antagonists of the CCR5 receptor, and highly selective and
potent inhibitors of PI3K δ based on an interesting new
molecular scaﬀold. Importantly, the compounds possess good
predicted lead- or druglike properties,15,62,32 giving extra
evidence for the scaﬀold to be considered privileged for
medicinal chemistry projects. In the DPP-4 case study, we have
shown the stereochemical preference for the cis-fused
diastereoisomer of the octahydro[1,2,4]triazolo[4,3-a][1,6]-
naphthyridine tricyclic ring system and have described initial
studies toward a diastereoselective synthesis of the new
Figure 12. Plot of PI3K isoform activity versus example number
demonstrating the general high level of PI3K δ isoform selectivity
observed with all examples. Highlighted are key compounds 72, 73,
and 78compounds that show the most favorable PI3K δ isoform
selectivity proﬁle.
Figure 13. Plot of PI3K δ activity versus group PI3K α activity
highlighting changes in group R2 showing the high PI3K δ isoform
selectivity imparted by the 4-substituted indole (group F).
Figure 14. Matched-pair analysis for the acyclic scaﬀold containing
compounds (groups A) and the cis-fused tricyclic containing scaﬀold
(groups B) showing a general trend for an increase in PI3K δ isoform
activity through the inclusion of the cis-fused tricyclic scaﬀold.
Figure 15. Matched-pair analysis for the acyclic scaﬀold containing
compounds (groups A) and the trans-fused tricyclic containing scaﬀold
(groups C) showing a general trend for an increase in PI3K δ isoform
activity through the inclusion of the trans-fused tricyclic scaﬀold.
Figure 16. Plot of PI3K δ activity as a function of PI3K δ isoform
selectivity (vs PI3K α), highlighting changes to group R1.
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molecular scaﬀold resulting in determination of the absolute
conﬁguration of the eutomer. Further work is ongoing in our
laboratories on the incorporation of the new molecular scaﬀold
into new compounds to interact with biological targets, and
these will be reported in due course.
■ EXPERIMENTAL SECTION
ChemistryGeneral Methods. All reactions with air- and
humidity-sensitive reagents were carried out under an atmosphere of
nitrogen. The ﬂasks were ﬂushed with nitrogen. The liquids were
added using plastic syringes. All starting materials, reagents and
solvents were purchased from commercial suppliers e.g. Acros, Sigma-
Aldrich, Fluorochem, Key Organics and Merck. All solvents were
either analytical reagent or HPLC grade and were supplied by Fisher
Scientiﬁc. Dry solvents were used for all reactions and were purchased
from Sigma-Aldrich and VWR. The petroleum ether had a boiling
point of 40 to 60 °C. CDCl3 was supplied by Cambridge Isotope
Laboratories, Inc., MeOD4 was supplied by Sigma-Aldrich. All
reactions were monitored for completion using TLC. Therefore,
commercially available precoated silica gel 60 F254 aluminum plates
from Merck were used. Visualization of the spots was carried using the
UV-lamp (λ = 254 nm) and stained with KMnO4 or iodine and
subsequently heated. Flash column chromatography was carried out
using silica gel, technical grade, pore size 60 Å, 230−400 mesh particle
size, 40−60 μm particle size purchased from Sigma-Aldrich. The 13C-
and 1H NMR spectra were recorded using a Bruker AV (II) 500
spectrometer with a magnetic ﬁeld strength of 9.4T. This is
corresponding to a resonance frequency of 400 MHz for protons
and around 100 MHz for the 13C nucleus. All 13C NMR are 1H-
broadband-decoupled. The chemical shifts δ are given in [ppm] and all
coupling constants J are given in [Hz]. The spectra are referenced to
the signal of the deuterated solvent: CDCl3 (δH= 7.26, δC= 77.16
ppm) or MeOD4 (δH= 3.31, δC= 49.00 ppm). The following
abbreviations were used to describe signal shapes and multiplicity: s
(singlet), bs (broad singlet), d (doublet), dd (doublet of doublet), ddd
(doublet of doublet of a doublet), dddd (doublet of a doublet of a
doublet of a doublet), t (triplet), dt (doublet of a triplet), q (quartet),
dq (doublet of a quartet) and m (multiplet). Furthermore, 2D-NMR
experiments: COSY and HSQC were used for the assignment of the
signals and the processing of the NMR data was carried out using the
NMR software TopSpin 3.0. All high-resolution mass spectra
(HRMS)- time to ﬂight electrospray were recorded on a Waters
2795 spectrometer by electrospray ionization (TOF ES) and the LC-
MS spectra were performed on a Shimadzu UFLCXR system coupled
to an Applied Biosystems API2000, and visualized at 220 nm (channel
2) and 254 nm (channel 1). LC-MS was carried out using a
Phenomenex Gemini-NX C18 110A, column (50 mm × 2 mm x 3
μm) at a ﬂow rate 0.5 mL/min over a 5 min period - method (A).
Analytical RP-HPLC was performed using a Waters 2767 sample
manager, Waters 2525 binary gradient module, and visualized at 220
nm with a Waters 2487 dual wavelength absorbance detector - method
(B). Spectra were analyzed using MassLynx. Preparative HPLC was
performed using a Phenomenex Gemini-NX 5u C18 110A, AXIA
packed column (160 mm × 21.2 mm) at a ﬂow rate of 20 mL/min,
typically starting with 90% water/10% acetonitrile and progressing to
100% acetonitrile over 40 min. The water phase contained 0.01%
ammonia. Chiral analytical HPLC was performed using a Phenomenex
LC Lux 5u Amylose-2 packed column (250 × 4.6 mm) at a ﬂow rate of
1.5 mL/min, isocratically using 70% hexane: 30% ethanol
supplemented with 0.2% DEA over 30 min - method (C).
All compounds submitted for biological screening had a purity
>95% determined through either methods (A), (B) or (C).
General Procedure 1,2,4-Triazole Formation. To a solution of
ethyl 2-thioxooctahydro-1, 6-naphthyridine-6(2H)-carboxylate (15
and 16) (2.43 mmol, 1 equiv) in toluene (20 mL) was added the
corresponding hydrazide (4.86 mmol, 2 equiv) and the mixture was
reﬂuxed at 110 °C for 48 h. The solvent was evaporated and the crude
product was puriﬁed by ﬂash chromatography (dichloromethane/
methanol 10:1) to yield the substituted triazoles (17−23).
General Procedure for the Removal of the Carbamate Protecting
Group. To a solution of the protected substituted triazole (17−23,
0.41 mmol, 1 equiv) in ethanol (0.44 mL) and water (2.50 mL) was
added KOH (1.80 mmol, 2.0−4.4 equiv) and the mixture was reﬂuxed
at 110 °C for 20 h. The reaction mixture was extracted with DCM (10
mL). The organic phase was dried over MgSO4, ﬁltered and the
solvent was evaporated and the crude product was used without
further puriﬁcation.
(R)-3-Amino-1-((5S,9R)-1-(triﬂuoromethyl)-4,5,5a,8,9,9a-hexahy-
dro-[1,2,4]triazolo[4,3-a][1,6]naphthyridin-7(6H)-yl)-4-(2,4,5-
triﬂuorophenyl)butan-1-one Hydrochloride (2). By the general
experimental procedures outlined above (R)-3-amino-1-((5S,9R)-1-
(triﬂuoromethyl)-4,5,5a,8,9,9a-hexahydro-[1,2,4]triazolo[4,3-a][1,6]-
naphthyridin-7(6H)-yl)-4-(2,4,5-triﬂuorophenyl)butan-1-one hydro-
chloride was prepared from ethyl (4S, 8R)-2-thioxooctahydro-1,6-
naphthyridine-6(2H)-carboxylate 12.
1H NMR (400 MHz, MeOD4) δ 7.46−7.36 (m, 1H), 7.27−7.18
(m, 1H), 4.68 (t, J = 17.5 Hz, 1H), 4.01 (dd, J = 15.7, 30.6 Hz, 1H),
3.86 (bs, 1H), 3.76−3.50 (m, 1H), 3.39−3.25 (m, 2H), 3.22−3.07 (m,
3H), 2.92−2.81 (m, 3H), 2.49 (m, 1H), 2.18−2.10 (m, 2H), 2.02−
1.94 (m, 2H) ppm. LC/MS m/z: 462.2 [M + H]+, 2.02 min. HPLC: >
98% (method A), 93:7 mixture of enantiomers (method C).
Ethy l (3R ,4S) -3- (3-Ethoxy-3-oxopropy l ) -4- ( ( (R ) -1- (4-
methoxyphenyl)ethyl)amino)piperidine-1-carboxylate (10). To
ethyl 3-(3-ethoxy-3-oxopropyl)-4-oxopiperidine-1-carboxylate (2.0 g,
7.4 mmol, 1 equiv) in 1,2 dichloroethane (32 mL) was added (S)-1−
1(4-methoxy-phenyl) ethylamine (1.2 mL, 7.9 mmol, 1.1 equiv) and
NaBH(OAc)3 (2.2 g, 10.4 mmol, 1.4 equiv) and the reaction was
stirred overnight. The reaction mixture was diluted with saturated
aqueous NaHCO3 (50 mL) and the aqueous phase was extracted with
ethyl acetate (3 × 50 mL). The combined organic phases were dried
over Na2SO4, ﬁltered and the solvent was evaporated under reduced
pressure. The crude product was puriﬁed using ﬂash chromatography
(ethyl acetate/petrol ether+ NH4OH, 10:1) to yield amine 10 (600
mg, 20%)
1H NMR (400 MHz, CDCl3) δ/ppm 7.19 (d, J = 9.2 Hz, 2H), 6.84
(d, J = 8.1 Hz, 2H), 4.18−4.04 (m, 6H), 3.78 (s, 5H), 2.83- 2.74 (m,
2H), 2.61−2.57 (m, 1H), 2.51−2.28 (m, 1H), 1.83−1.68 (m, 2H),
1.48−1.37 (m, 4H), 1.30−1.20 (m, 9H) ppm. 13C NMR (100 MHz,
CDCl3) δ/ppm 173.8, 158.6, 155.9, 137.9, 127.6, 113.9, 61.3, 60.4,
55.4, 54.0, 44.9, 40.8, 36.6, 32.2, 25.1, 19.1, 14.7 ppm. LC/MS m/z:
407.6 [M + H]+.
Ethyl (4S,8R)-2-Oxooctahydro-1,6-naphthyridine-6(2H)-carboxy-
late (11). To (3R, 4S)-3-(3-ethoxy-3-oxopropyl)-4-(((R)-1-(4-me-
thoxyphenyl) ethyl) amino) piperidine-1-carboxylate 10 (600 mg, 1.5
mmol, 1 equiv) in ethanol was added ammonium formate (400 mg,
6.3 mmol, 4.2 equiv) and Pd/C (small spatula) and heated to 50 °C
for 8 h. The reaction mixture was ﬁltered over Celite and the ﬁltrate
was evaporated under reduced pressure. The crude product was
puriﬁed by ﬂash chromatography (ethyl acetate/petrol ether 10:1 +
10% methanol) to yield lactam 11 (150 mg, 51%) as colorless oil.
1H NMR (400 MHz, CDCl3) δ 7.33 (bs, 1H), 4.11−4.04 (m, 2H),
3.57−3.51 (m, 3H), 3.40−3.36 (m, 1H), 3.26−3.20 (m, 1H), 3.15 (t,
J= 6.9 Hz, 2H), 2.03−1.98 (m, 1H), 1.86−1.62 (m, 4H), 1.20 (t, J=
7.2 Hz, 3H) ppm. 13C NMR (100 MHz, CDCl3) δ 172.6, 155.6, 61.7,
50.6, 44.7, 40.5, 32.7, 30.5, 28.9, 22.0, 14.9 ppm. HRMS m/z:
C14H19N2O3 calculated 227.1390 [M + H]
+, found 227.6533.
Ethyl (4S,8R)-2-Thioxooctahydro-1,6-naphthyridine-6(2H)-car-
boxylate (12). To a solution of ethyl (4R, 8S)-2-oxooctahydro-1,6-
naphthyridine-6(2H)-carboxylate 10 (80 mg, 0.35 mmol, 1.0 equiv) in
toluene (1 mL) was added Lawesson’s reagent (71 mg, 0.17 mmol, 0.5
equiv) and the mixture was reﬂuxed for 20 min. The reaction mixture
was evaporated under reduced pressure and puriﬁed by ﬂash
chromatography (ethyl acetate/petrol ether: 10:1) to yield ethyl (4S,
8R)-2-thioxooctahydro-1, 6-naphthyridine-6(2H)-carboxylate 12 as a
colorless waxy oil (90%). 1H NMR (400 MHz, CDCl3) δ 9.83 (bs,
1H), 4.11−4.04 (m, 2H), 3.60−3.50 (m, 3H), 3.40−3.34 (m, 1H),
3.26−3.17 (m, 1H), 2.94−2.77 (m, 2H), 2.05−2.01 (m, 1H), 1.81−
1.70 (m, 4H), 1.19 (t, J= 7.0 Hz, 3H) ppm. 13C NMR (100 MHz,
CDCl3) δ 202.1, 155.7, 61.7, 53.1, 44.9, 40.6, 37.7, 31.7, 29.3, 21.4,
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14.9 ppm. HRMS m/z: C11H19H2O2S calculated 243.1162 [M + H]
+,
found 243.0112.
rel-Ethyl (5S,9R)-1-Methyl-4,5,5a,8,9,9a-hexahydro-[1,2,4]-
triazolo[4,3-a][1,6]naphthyridine-7(6H)-carboxylate (17). 1H NMR
(400 MHz, CDCl3) δ 4.20 (bs, 2H), 4.11−4.00 (m, 3H), 3.08−2.96
(m, 2H), 2.78−2.67 (m, 2H), 2.31 (s, 3H), 2.12−2.08 (m, 1H), 1.95−
1.75 (m, 3H), 1.60 (qd, J = 5.6, 13.3 Hz, 1H), 1.16 (t, J = 7.1 Hz, 3H)
ppm. 13C NMR (100 MHz, CDCl3) δ 155.5, 149.8, 148.9, 61.6, 51.8,
47.2, 42.1, 33.7, 28.1, 20.9, 19.3, 14.5, 10.3 ppm. HRMS m/z:
C13H21N4O2 calc. 265.1659 [M + H]
+, found 265.2795.
rel-Ethyl (5S,9R)-1-Isopropyl-4,5,5a,8,9,9a-hexahydro-[1,2,4]-
triazolo[4,3-a][1,6]naphthyridine-7(6H)-carboxylate (18, 75%
yield). 1H NMR (400 MHz, CDCl3) δ 4.26 (bs, 2H), 4.18−4.07
(m, 2H), 3.13 (dd, J = 5.6, J = 17.0 Hz, 1H), 3.08 (bs, 1H), 2.91−2.77
(m, 4H), 2.16 (d, J = 11.1 Hz, 1H), 2.03−1.92 (m, 1H), 1.90−1.84
(m, 2H), 1.70 (ddd, J = 3.9, 12.5, 26.1 Hz, 1H), 1.40 (d, J = 6.6 Hz,
3H), 1.30 (d, J = 6.9 Hz, 3H), 1.22 (t, J = 7.3 Hz, 3H) ppm. 13C NMR
(100 MHz, CDCl3) δ 174.1, 157.7, 155.7, 149.4, 61.8, 52.2, 42.8, 33.9,
29.1, 22.7, 21.3, 21.1, 19.7, 14.6 ppm. HRMS m/z: C15H25N4O2 calc.
293.1972 [M + H]+, found 293.1961.
rel-Ethyl (5S,9R)-1-Benzyl-4,5,5a,8,9,9a-hexahydro-[1,2,4]-
triazolo[4,3-a] [1,6]naphthyridine-7(6H)-carboxylate (19, 54%
Yield). 1H NMR (400 MHz, MeOD4) δ 7.32−7.17 (m, 5H), 4.25−
4.03 (m, 7H), 3.11−3.03 (dd, J = 6.0, 17.0, 2H), 2.87−2.75 (ddd, J =
7.7, 12.1, 19.8 Hz, 2H), 2.09 (d, J = 10.9 Hz, 1H), 1.89−1.83 (m, 1H),
1.79 (dq, J = 4.8, 12.1 Hz, 1H), 1.67−156 (m, 2H), 1.22 (t, J = 7.4 Hz,
3H) ppm. 13C NMR (100 MHz, MeOD4) δ 173.0, 157.3, 153.3, 136.5,
129.9, 129.4, 127.8, 62.7, 53.4, 43.1, 41.4, 34.7, 31.2, 28.9, 21.5, 19.9,
14.8 ppm. LCMS m/z: 341.4 [M + H]+.
rel-Ethyl (5S,9R)-1-(Pyridin-2-yl)-4,5,5a,8,9,9a-hexahydro-[1,2,4]-
triazolo[4,3-a][1,6]naphthyridine-7(6H)-carboxylate (20, 31%
Yield). 1H NMR (400 MHz, CDCl3) δ 8.54 (d, 0.67H), 8.47 (m,
0.33H), 8.24 (d, J = 8.0 Hz, 0.67H), 8.0 (d, J = 9.0 Hz, 0.33H), 7.82−
7.71 (m, 1H), 7.36 (t, J = 6.5 Hz, 0.33 H), 7.26 (t, J = 5.2 Hz, 0.67H),
5.43 (dt, J = 2.9, 10.4 Hz, 1H), 4.22 (bs, 2H), 4.11−4.04 (m, 2H), 3.28
(bd, J = 15.0 Hz, 1H), 3.12 (bs, 1H), 2.94−2.78 (m, 2H), 2.32 (d, J =
15.0 Hz, 1H), 2.08−1.96 (m, H-3, 2H), 1.87 (bs, 1H), 1.55 (ddd, J =
4.6, 12.8, 24.5 Hz, 1H), 1.19 (t, J = 6.8 Hz, 3H) ppm. 13C NMR (100
MHz, CDCl3) δ 155.8, 148.8, 148.5, 148.4, 126.9, 126.7 (2), 125.5,
122.8, 122.6, 122.2, 61.7, 54.4, 50.5, 47.4, 42.6, 40.4, 21.4, 19.2, 14.7
ppm. LCMS m/z 328.2[M + H]+.
rel-Ethyl (5S,9R)-1-(Pyrazin-2-yl)-4,5,5a,8,9,9a-Hexahydro-[1,2,4]-
triazolo[4,3-a][1,6]naphthyridine-7(6H)-carboxylate (21, 33%
Yield). 1H NMR (400 MHz, CDCl3) δ 9.56 (s, 0.7 H), (s, 0.3 H),
8.56, 8.54, 8.53, 8.50, 8.49 (ms, 2H), 5.28 (dt, J = 4.2, 11.3 Hz, 1H),
4.26 (bs, 2H), 4.15−4.07 (m, 2H), 3.29 (dd, J = 6.1, 17.5 Hz, 1H),
3.13 (bs, 1H), 2.96 (ddd, J = 8.1, 12.3, 19.7 Hz, 1H), 2.84 (m, 1H),
2.27 (d, J = 13.5 Hz, 1H), 2.09−2.02 (m, 2H), 1.93 (bs, 1H), 1.63 (dq,
J = 4.5, 12.2 Hz, 1H), 1.22 (t, J = 6.7 Hz, 3H) ppm. 13C NMR (100
MHz, CDCl3) δ 163.3, 155.7, 152.6, 148.3, 147.7, 144.8, 144.2, 144.1,
143.8, 142.9, 142.8, 61.7, 54.5, 47.4, 42.6, 34.0, 28.9, 21.5, 19.3, 14.7
ppm. LCMS m/z 329.1 [M + H]+.
rel-Ethyl (5S,9R)-1-(2-Methylthiazol-4-yl)-4,5,5a,8,9,9a-hexahy-
dro-[1,2,4]triazolo[4,3-a][1,6]naphthyridine-7(6H)-carboxylate (22,
75% Yield). 1H NMR (400 MHz, CDCl3) δ 8.11 (s, 1H), 5.22 (dt, J =
4.2, 11.9 Hz, 1H), 4.26 (bs, H-4, 2H), 4.17−4.09 (m, 2H), 3.24 (dd, J
= 5.1, 16.7 Hz, 1H), 3.15 (bs, 1H), 2.92 (ddd, J = 7.2, 12.4, 20.1 Hz,
1H), 2.80 (bs, 1H), 2.75 (s, 3H), 2.25 (d, J = 11.2 Hz, 1H), 2.09−2.05
(m, 2H), 1.92 (bs, 1H), 1.60 (dq, J = 5.4, 12.5 Hz, 1H), 1.24 (t, J = 7.1
Hz, 3H) ppm. 13C NMR (100 MHz, CDCl3) δ 166.7, 155.9, 150.8,
147.5, 142.6, 120.2, 61.8, 54.1, 47.5, 42.7, 34.0, 28.9, 21.5, 19.7, 19.5,
14.8 ppm. LCMS m/z 348.2 [M + H]+.
rel-Ethyl (5R,9R)-1-Isopropyl-4,5,5a,8,9,9a-hexahydro-[1,2,4]-
triazolo[4,3-a][1,6]naphthyridine-7(6H)-carboxylate: (23, 30%
Yield). 1H NMR (400 MHz, CDCl3) δ 4.31(m, 2H), 4.09 (q, J =6.8
Hz, 2H), 3.66 (dt, J = 3.8, 11.1 Hz, 1H), 3.14 (ddd, J = 1.5, 4.1, 16.0
Hz, 1H), 3.03 (sept, J = 6.7 Hz, 1H), 2.91 (bs, 1H), 2.79 (ddd, J = 6.0,
13.1, 19.5 Hz, 1H), 2.66 (bs, 1H), 2.59 (bs, 1H) 1.87 (dd, J = 6.1, 13.3
Hz, 1H), 1.78−1.62 (m, 2H), 1.49 (ddd, J = 4.6, 12.7, 25.0 Hz, 2H),
1.38 (d, J = 6.6 Hz, 3H), 1.28 (d, J = 7.1 Hz, 3H), 1.21 (t, J = 6.1 Hz,
3H) ppm. 13C NMR (100 MHz, CDCl3) δ 174.1, 158.3, 155.2, 151.1,
61.8, 59.6, 47.8, 42.5, 41.3, 33.4, 30.8, 24.2, 22.8, 21.5, 21.1 ppm.
HRMS m/z: C15H25N4O2 calc. 293.1972 [M + H]
+, found 293.1517.
rel-(5S,9R)-1-Methyl-4,5,5a,6,7,8,9,9a-octahydro-[1,2,4]triazolo-
[4,3-a][1,6]naphthyridine (24, 65% Yield). 1H NMR (400 MHz,
CDCl3) δ 4.03 (dt, J = 5.1, 11.7 Hz, 1H), 3.17−3.07 (m, 3H), 2.98
(dd, J = 4.1, 12.7 Hz, 1H), 2.83−2.73 (qd, J = 6.5, 12.7 Hz, 1H), 2.67
(dt, J = 3.1, 13.1 Hz, 1H), 2.36 (s, 3H), 2.28 (ddd, J = 7.6, 13.8, 23.8
Hz, 1H), 2.06−2.01 (m, 1H), 1.94 (bs, 1H), 1.88−1.82 (m, 1H),
1.79−1.73 (m, 1H), 1.63 (ddd, J = 4.8, 12.6, 25.3 Hz, 1H) ppm. 13C
NMR (100 MHz, CDCl3) δ 150.5, 149.2, 52.6, 50.6, 45.2, 34.1, 29.7,
21.6, 20.2, 10.5 ppm. HRMS m/z: C10H17N4 calc. 193.1448 [M + H]
+,
found 193.1507.
rel-(5S,9R)-1-Isopropyl-4,5,5a,6,7,8,9,9a-octahydro-[1,2,4]-
triazolo[4,3-a][1,6]naphthyridine (25, 68% Yield). 1H NMR (400
MHz, CDCl3) δ 4.07 (dt, J = 4.8, 10.2 Hz, 1H), 3.18−3.07 (m, 3H),
3.00−2.97 (dd, J = 3.7, 12.8 Hz, 1H), 2.91−2.75 (m, 2H), 2.67 (dt, J =
3.3, 12.8 Hz, 1H), 2.36−2.23 (m, 1H), 2.04 (bd, J = 13.7 Hz, 1H),
1.85- 1.82 (m, 1H), 1.78−1.71 (m, 2H), 1.67 (ddd, J = 4.4, 12.8, 24.9
Hz, 1H), 1.39 (d, J = 6.7 Hz, 3H), 1.30 (d, J = 6.7 Hz, 3H) ppm.
HRMS m/z: C12H21N4 calc. 221.1761 [M + H]
+, found 221.1447.
rel-(5S,9R)-1-Benzyl-4,5,5a,6,7,8,9,9a-octahydro-[1,2,4]triazolo-
[4,3-a][1,6]naphthyridine (26, 80% Yield). 1H NMR (400 MHz,
CDCl3) δ 7.30−7.20 (m, 5H), 4.25 (d, J = 16.3 Hz, 1H), 4.02 (d, J =
16.3 Hz, 1H), 3.83 (dt, J = 5.3, 11.4, 1H), 3.18 (ddd, J = 1.7, 6.5, 17.1
Hz, 1H), 3.09−3.00 (m, 2H), 2.53 (dt, J = 3.4, 12.3 Hz, 1H), 2.29
(ddd, J = 5.9, 12.9, 26.0 Hz, 1H), 1.94 (m, 1H), 1.77−1.56 (m, 2H)
ppm. HRMS m/z: C16H21N4 calc. 269.1761 [M + H]
+, found
269.2529.
rel-(5S,9R)-1-(6-Ethoxypyridin-2-yl)-4,5,5a,6,7,8,9,9a-octahydro-
[1,2,4]triazolo[4,3-a][1,6]naphthyridine (27, 67% Yield). 1H NMR
(400 MHz, CDCl3) δ 7.90 (dd, J = 0.8, 7.6 Hz, 1H), 7.66 (dd, J = 6.8,
8.2 Hz, 1H), 6.74 (dd, J = 0.8, 8.2 Hz, 1H), 5.36 (dt, J = 5.0, 11.7 Hz,
1H), 4.42−4.24 (m, 2H), 3.31 (ddd, J = 1.0, 5.6, 17.4 Hz, 1H), 3.23 (t,
J = 13.1 Hz, 1H), 3.13 (m, 1H), 3.04 (dd, J = 3.3, 12.4 Hz, 1H), 2.95
(ddd, J = 6.0, 12.5, 17.2 Hz, 1H), 2.66 (td, J = 3.0, 13.0 Hz, 3H), 2.41
(ddd, J = 5.6, 13.0, 25.9 Hz, 1H), 2.27−2.22 (m, 1H), 2.14−2.09 (m,
1H), 1.88−1.81 (m, 1H), 1.68 (ddd, J = 4.1, 12.5, 24.5 Hz, 1H), 1.42
(t, J = 7.1 Hz, 3H) ppm. HRMS m/z: C16H22N5O calc. 300.1819 [M +
H]+, found 300.4049.
rel-(5S,9R)-1-(Pyridin-2-yl)-4,5,5a,6,7,8,9,9a-octahydro-[1,2,4]-
triazolo[4,3-a][1,6]naphthyridine (28, 59% Yield). 1H NMR (400
MHz, CDCl3) δ 8.57 (dq, J = 0.8, 4.4 Hz, 1H), 8.25 (dt, J = 1.0, 8.1
Hz, 1H), 7.75 (dt, J = 1.9, 7.9 Hz, 1H), 7.26 (dd, J = 1.2, 4.2 Hz, 1H),
5.38 (dt, J = 5.3, 12.2 Hz, 1H), 3.28 (ddd, J = 1.3, 5.9, 17.0 Hz, 1H),
3.13 (m, 1H), 3.06−2.99 (m, 2H), 2.91 (ddd, J = 6.8, 12.1, 17.6 Hz,
1H), 2.68 (dt, J = 2.8, 12.7 Hz, 1H), 2.35 (ddd, J = 5.8, 13.1, 26.2 Hz,
1H), 2.21−2.15 (m, 1H), 2.10−1.94 (m, 2H), 1.83−1.76 (m, 1H),
1.53 (ddd, J = 4.3, 12.5, 25.5 Hz, 1H) ppm. LCMS m/z: 256.0 [M +
H]+, 0.42 min.
rel-(5S,9R)-1-(Pyrazin-2-yl)-4,5,5a,6,7,8,9,9a-octahydro-[1,2,4]-
triazolo[4,3-a][1,6]naphthyridine (29, 54% Yield). 1H NMR (400
MHz, CDCl3) δ 9.55 (d, J = 1.3 Hz, 1H), 8.56−8.55 (m, 2H), 5.24
(dt, J = 4.8, 11.0 Hz, 1H), 3.33 (ddd, J = 1.0, 5.8, 17.0 Hz, 1H), 3.17
(dt, J = 1.6, 13.0 Hz, 1H), 3.10−3.03 (m, 2H), 2.96 (ddd, J = 7.0, 12.6,
17.3 Hz, 1H), 2.71 (dt, J = 2.6, 12.6 Hz, 1H), 2.40 (ddd, J = 5.8, 12.6,
25.8 Hz, 1H), 2.19−2.03 (m, 1H), 1.90−1.80 (m, 4H), 1.60 (ddd, J =
4.7, 12.4, 24.2 Hz, 1H) ppm.
rel-2-Methyl-4-((5S,9R)-4,5,5a,6,7,8,9,9a-octahydro-[1,2,4]-
triazolo[4,3-a][1,6]naphthyridin-1-yl)thiazole (30, 87% Yield). 1H
NMR (400 MHz, CDCl3) δ 7.91 (s, 1H), 5.16−5.10 (m, 1H), 3.26
(dd, J = 6.1, 16.9 Hz, 1H), 3.14 (m, 1H), 3.07−3.02 (m, 2H), 2.94−
2.84 (m, 1H), 2.73 (s, 3H), 2.69−2.62 (t, J = 11.2 Hz, 1H), 2.36 (ddd,
J = 5.1, 12.7, 25.9 Hz, 1H), 2.16 (d, J = 14.1 Hz, 1H), 1.94 (d, J = 12.5
Hz, 1H), 1.83−1.77 (m, 2H), 1.60−1.50 (m, 1H) ppm. LC/MS m/z:
276.2 [M + H]+.
rel-(5R,9R)-1-Isopropyl-4,5,5a,6,7,8,9,9a-octahydro-[1,2,4]-
triazolo[4,3-a][1,6]naphthyridine (31, 48% Yield). 1H NMR (400
MHz, CDCl3) δ 3.64 (dt, J = 3.3, 11.2 Hz, 1H), 3.25−3.17 (m, 1H),
3.17−3.04 (m, 3H), 2.86−2.78 (m, 2H), 2.61−2.54 (m, 2H), 2.03 (bs,
1H), 1.83−1.64 (m, 3H), 1.54−1.46 (ddd, J = 4.3, 11.1, 23.2 Hz, 1H),
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1.42 (d, J = 6.7 Hz, 3H), 1.30 (d, J = 6.7 Hz, 3H) ppm. HRMS m/z:
C12H21N4 calc. 221.1761 [M + H]
+, found 221.1684.
General Procedure for Amide Coupling. To a solution of amine
(24-31, 0.33 mmol, 1 equiv) in DMF (1 mL) was added (R)-3-((tert-
butoxycarbonyl)amino)-4-(2,4,5-triﬂuorophenyl)butanoic acid EDCI
(0.38 mmol, 1.2 equiv) and HOBt (0.38 mmol, 1.2 equiv) and the
mixture was stirred at RT overnight. The reaction mixture was diluted
with ethyl acetate (20 mL) and saturated aqueous NaHCO3 (20 mL).
The water phase was extracted with ethyl acetate (3 × 20 mL). The
combined organic phases were washed with saturated aqueous sodium
chloride (20 mL), dried over Na2SO4, ﬁltered and the crude product
was puriﬁed by ﬂash chromatography (dichloromethane/methanol:
10:1) to yield the amide.
General Method for boc-Deprotection. To the above amides (32-
39, 0.08 mmol, 1 equiv) was added 4 N HCl in 1,4-dioxane (0.5 mL)
and the reaction mixture was stirred at RT for 30 min. The excess
hydrogen chloride solution was evaporated under N2 gas to yield the
hydrochloride salt of the amines as oils.
rel-tert-Butyl ((R)-4-((5S,9R)-1-Methyl-4,5,5a,8,9,9a-hexahydro-
[1,2,4]triazolo[4,3-a][1,6]naphthyridin-7(6H)-yl)-4-oxo-1-(2,4,5-
triﬂuorophenyl)butan-2-yl)carbamate (32, 45% Yield). 1H NMR
(400 MHz, MeOD4) δ 7.22−7.16 (m, 1H), 7.14−7.04 (m, 1H), 6.68−
6.56 (m, 1H), 4.72 (t, J = 13.8 Hz, 0.5H), 4.63 (m, 0.5H), 4.54−4.46
(m, 1H), 4.23−4.01 (m, 2H), 3.56−3.48 (m, 0.5H), 3.35−3.24 (m,
3H), 3.14−2.47 (m, 6H), 2.44 (s, Me, 3H), 2.35−2.27 (m, 1H), 2.14−
1.63 (m, 3H), 1.34−1.24 (3s, 9H) ppm. HRMS m/z: C25H33N5F3O3
calc. 508.2530 [M + H]+, found 508.3067.
tert-Butyl ((R)-4-((5S*,9R*)-1-Isopropyl-4,5,5a,8,9,9a-hexahydro-
[1,2,4]triazolo[4,3-a][1,6]naphthyridin-7(6H)-yl)-4-oxo-1-(2,4,5-
triﬂuorophenyl)butan-2-yl)carbamate (33; 64% Yield). 1H NMR
(400 MHz, CDCl3) δ 7.07−7.00, 6.89 (m, 1H), 5.56−5.37 (m, 1H),
4.82−4.72 (m, 1H), 4.24−4.20 (m, 1H), 4.10 (bs, 1H), 4.00−3.89 (m,
1H), 3.38 (m, 0.5H), 3.17−3.08 (m, 1.5H), 2.97−2.80 (m, 4H), 2.71−
2.47 (m, 3H), 2.23 (bs, 1H), 1.99−1.62 (m, 4H), 1.42−1.39 (m,, 3H),
1.32−1.30 (m, 12H) ppm.13CNMR(100 MHz, CDCl3) δ 169.7, 157.7,
157.4, 155.0, 149.4, 149.1, 147.9, 147.7, 145.4, 143.2, 128.6, 126.5,
124.4, 121.8, 119.2, 112.1, 110.3, 105.1, 79.6, 52.1, 49.2, 48.4, 45.1,
44.2, 44.1, 40.1, 34.0, 33.9, 33.8, 28.9, 26.4, 24.5, 21.7, 21.2, 19.6, 19.4
ppm. HRMS m/z: C27H37N5F3O3 calc. 536.2843 [M + H]
+, found
536.2856.
(R)-3-Amino-1-((5S*,9R*)-1-benzyl-4,5,5a,8,9,9a-hexahydro-
[1,2,4]triazolo[4,3-a][1,6]naphthyridin-7(6H)-yl)-4-(2,4,5-
triﬂuorophenyl)butan-1-one Hydrochloride (34, 98% Yield). HPLC
(tR= 11.01 min, 100%).
1H NMR (400 MHz, MeOD4) δ 7.41−7.29
(m, 5H), 7.26−7.20 (m, 2H), 4.75−4.64 (m, 1H), 4.39 (q, 2H), 3.89−
3.76 (m, 3H), 3.13−2.99 (m, 4H), 2.79−2.55 (m, 4H), 2.09−1.67 (m,
3H) ppm. 13C NMR (100 MHz, MeOD4) δ 173.1, 170.4, 169.9, 159.0,
157.0, 152.1, 151.9, 150.1, 149.9, 149.3, 149.1, 147.3, 130.2, 130.1,
128.9, 120.4, 107.0, 54.6, 45.7, 44.7, 36.4, 36.3, 34.8, 34.2, 32.4, 32.3,
30.9, 30.7, 29.0, 28.4, 20.8, 18.7 ppm. HRMS m/z: C26H29N5F3O calc.
484.2389 [M + H]+, found 484.2330.
tert-Butyl ( (R)-4-( (5S* ,9R* ) -1-(6-Ethoxypyr id in-2-yl ) -
4,5,5a,8,9,9a-hexahydro[1,2,4]triazolo[4,3-a][1,6]naphthyridin-
7(6H)-yl)-4-oxo-1-(2,4,5-triﬂuorophenyl)butan-2-yl)carbamate (35,
98% Yield). 1H NMR (400 MHz, CDCl3) δ 8.07−7.95 (m, 1H),
7.82−7.72 (m, 1H), 7.61−7.51 (m, 0.5H), 7.50−7.40 (m, 0.5H),
7.13−7.02 (m, 1H), 6.98−6.86 (m, 1H), 5.70−5.34 (m, 1H), 5.00−
4.75 (m, 1H), 4.43−4.33 (m, 1H), 4.29−4.22 (m, 0.5H), 4.14−3.87
(m, 1.5H), 3.61−3.45 (m, 3H), 3.16−2.82 (m, 6H), 2.74−2.41 (m,
2H), 2.38−2.26 (m, 1H), 2.16−1.90 (m, 2H), 1.81−1.69 (m, 1H),
1.48−1.30 (m, 12H) ppm. LC/MS m/z: 615.3 [M + H]+.
tert-Butyl ((R)-4-Oxo-4-((5S*,9R*)-1-(pyridin-2-yl)-4,5,5a,8,9,9a-
hexahydro[1,2,4]triazolo[4,3-a][1,6]naphthyridin-7(6H)-yl)-1-(2,4,5-
triﬂuorophenyl)butan-2-yl)carbamate (36, 37% Yield). 1H NMR
(400 MHz, CDCl3) δ 8.60−8.57 (m, 1H), 8.29 (d, J =7.9 Hz, 1H),
7.79 (dt, J =1.3, 7.8 Hz, 1H), 7.32−7.28 (m, 1H), 7.08−7.00(m, 1H),
6.89−6.80 (m, 1H), 5.60−5.40 (m, 2H), 4.83 (d, J = 14.0 Hz, 0.5 H),
4.72−4.65 (m, 0.5H), 4.13−4.01 (m, 1H), 3.92 (t, J = 15.1, 0.5H),
3.83−3.76 (m, 0.5H), 3.47−3.41 (m, 0.5H), 3.34−3.23 (m, 1H), 3.15
(dt, J = 2.7, 13.0 Hz, 0.5H), 3.03−2.85 (m, 4H), 2.70−2.47 (m, 3H),
2.40−2.32 (m, 1H), 2.27−2.15 (m, 1H), 2.10−1.91 (m, 1H), 1.66−
1.48 (m, 1H), 1.35−1.33 (m, 9H) ppm. 13C NMR (100 MHz, CDCl3)
δ 169.6, 169.4, 157.6, 155.4, 155.0, 151.9, 151.6, 150.4, 150.1, 148.8,
148.1, 147.8, 147.7, 145.4, 137.2, 124.0, 123.3, 119.3, 105.4, 79.5, 54.2,
49.3, 49.1, 48.5, 44.5, 40.5, 34.3, 34.2, 34.1, 34.0, 33.4, 33.1, 29.4, 28.3,
21.6, 21.5, 19.6, 19.4 ppm. LC/MS m/z: 571.2 [M + H]+.
tert-Butyl ((R)-4-Oxo-4-((5S*,9R*)-1-(pyrazin-2-yl)-4,5,5a,8,9,9a-
hexahydro[1,2,4]triazolo[4,3-a][1,6]naphthyridin-7(6H)-yl)-1-(2,4,5-
triﬂuorophenyl)butan-2-yl)carbamate (37, 44% Yield). 1H NMR
(400 MHz, CDCl3) δ 8.68 (m, 1H, 1H), 7.80 (dd, J = 9.4 Hz, 1H),
7.43 (m, 1H), 7.09−7.01 (m, 1H), 6.90−6.86 (m, 1H), 5.51 (m, 1H),
4.86 (d, J = 12.5 Hz, 0.5H), 4.75 (m, 0.5H), 4.15−3.35 (m, 6H),
3.19−3.10 (m, 1H), 2.97−2.80 (m, 5H), 2.70−2.48 (m, 3H), 2.14−
1.89 (m, 2H), 1.35−1.31 (m, 9H) ppm. 13C NMR (100 MHz, CDCl3)
δ 173.6, 159.9, 157.3, 155.3, 145.8, 145.3, 145.2, 143.3, 142.8, 128.7,
127.0, 126.8, 119.2, 117.0, 111.6, 105.7, 105.4, 105.3, 79.8, 55.9, 55.1,
49.1, 48.9, 47.7, 45.0, 44.3, 37.8, 36.6, 35.5, 33.6, 33.2, 29.4, 28.4, 25.4,
21.2 (2), 18.8, 18.6 ppm. HRMS m/z: C28H33N7F3O3 calc. 572.2591
[M + H]+, found 572.2415.
tert-Butyl ((R)-4-((5S*,9R*)-1-(2-Methylthiazol-4-yl)-4,5,5a,8,9,9a-
hexahydro[1,2,4]triazolo[4,3-a][1,6]naphthyridin-7(6H)-yl)-4-oxo-1-
(2,4,5-triﬂuorophenyl)butan-2-yl)carbamate (38, 69% Yield). 1H
NMR (400 MHz, CDCl3) δ 8.01 (s, 0.5H), 7.97 (s, 0.5H), 7.07−6.99
(m, 1H), 6.90−6.81 (m, 1H), 5.62−5.40 (m, 1H), 5.33−5.24 (m, 1H),
4.81−4.64 (m, 0.5H), 4.14 (bm, 1H), 3.98−3.77 (m, 0.5H), 3.46−3.04
(3t, 1H), 2.98−2.82 (m, 6H), 2.74 (s, 3H), 2.67−2.45 (m, 2H), 2.33
(m, 1H), 2.21−2.09 (m, 1H), 2.06−1.74 (m, 1H), 1.67−1.49 (m, 1H),
1.34−1.30 (2s, 9H) ppm. HRMS m/z: C28H34N6F3O3S calc. 591.2360
[M + H]+, found 591.2156.
tert-Butyl ((R)-4-((5R*,9R*)-1-Isopropyl-4,5,5a,8,9,9a-hexahydro-
[1,2,4]triazolo[4,3-a][1,6]naphthyridin-7(6H)-yl)-4-oxo-1-(2,4,5-
triﬂuorophenyl)butan-2-yl)carbamate (39, 77% Yield). 1H NMR
(400 MHz, CDCl3) δ 7.10−7.04 (m, 1H), 6.92−6.86 (m, 1H), 5.48−
5.42 (m, 1H), 4.82 (dd, J = 13.2, 29.9 Hz, 1H), 4.14−3.93 (m, 1H),
3.79 (dt, J = 3.0, 10.9 Hz, 1H), 3.27−3.16 (m, 1H), 3.12−2.46, m,
9H), 2.00−1.87 (m, 1H), 1.84−1.67 (m, 2H), 1.64−1.51 (m, 1H),
1.45, 1.43 (2s, 3H), 1.35 (s, 9H), 1.33, 1.32 (2s, 3H) ppm. 13C NMR
(100 MHz, CDCl3) δ 169.2, 158.5, 158.4, 157.5, 155.4, 155.0, 151.7,
151.5, 150.1, 147.8, 147.5, 145.5, 143.3, 128.7, 126.5, 124.4, 122.0,
121.8, 119.3, 119.0, 105.6 105.4, 105.1, 79.6, 59.7, 59.5, 49.5, 48.4,
45.5, 44.3, 41.8, 41.2, 41.1, 36.6, 33.2, 31.4, 28.4, 27.0, 24.3, 22.8, 21.5,
21.2 ppm. HRMS m/z: C27H37N5F3O3 calc. 536.2843 [M + H]
+,
found 536.2926.
(R)-3-Amino-1-((5S*,9R*)-1-methyl-4,5,5a,8,9,9a-hexahydro-
[1,2,4]triazolo[4,3-a][1,6]naphthyridin-7(6H)-yl)-4-(2,4,5-
triﬂuorophenyl)butan-1-one Hydrochloride (40). 1H NMR (400
MHz, MeOD4) δ 7.45−7.38 (m, 1H), 7.29−7.21 (m, 1H), 4.81−4.66
(m, 2H), 4.08−4.02 (m, 0.5H), 3.99−3.94 (m, 0.5H), 3.89−3.82 (m,
1H), 3.57−3.49 (m, 0.5H), 3.31−3.18 (m, 1.5H), 3.15−3.03 (m, 3H),
2.94−2.73 (m, 2H), 2.64 (s, 3H), 2.44−2.40 (m, 1H), 2.20−1.87 (m,
4H) ppm. 13C NMR (100 MHz, MeOD4) δ 170.3, 170.0, 153.0, 152.6,
120.7, 107.2, 107.0, 106.8, 54.4, 49.8, 45.7, 44.6, 41.0, 34.9, 34.8, 34.2,
34.0, 32.4, 28.8, 28.0, 24.2, 20.9, 19.0, 18.9, 9.8 ppm. LCMS m/z:
408.2, [M + H]+. HPLC (tR= 9.60 min, 100% - method (b)).
(R)-3-Amino-1-((5S*,9R*)-1-isopropyl-4,5,5a,8,9,9a-hexahydro-
[1,2,4]triazolo[4,3-a][1,6]naphthyridin-7(6H)-yl)-4-(2,4,5-
triﬂuorophenyl)butan-1-one (41, 100% Yield). 1H NMR (400 MHz,
MeOD4) δ 7.40−7.32 (m, 1H), 7.30−7.21 (m, 1H), 4.69−4.62 (m,
3H), 4.02−3.96 (m, 0.5H), 3.93−3.80 (m, 2H), 3.55−3.48 (dt, J =3.6,
11.6 Hz, 0.5H), 3.28−3.21 (m, 1H), 3.17−3.10 (m, 1H), 3.08−3.03
(m, 3H), 3.00−2.66 (m, 4H), 2.38 (d, J = 12.7 Hz, 1H), 2.09−1.74
(m, 4H), 1.42 (2d, J = 6.7 Hz, 6.7 Hz, 3H), 1.37 (2d, J = 6.7 Hz, 6.7
Hz, 3H) ppm. 13C NMR (100 MHz, MeOD4) δ 170.4. 170.3, 170.0,
160.5, 152.7, 152.5, 128.8, 127.9, 120.7, 120.5, 118.3, 111.6, 107.2,
107.0, 106.8, 73.5, 72.4, 62.2, 54.7, 50.2, 45.6, 44.6, 41.0, 40.9, 34.9,
34.1, 33.9, 32.4, 29.6, 28.8, 21.9, 21.1, 20.7, 18.8 ppm. LC/MS m/z
436.5 [M + H]+, 1.85 min. HPLC (tR= 7.60 min, 100% - method (b)).
(R)-3-Amino-1-((5S*,9R*)-1-(6-ethoxypyridin-2-yl)-4,5,5a,8,9,9a-
hexahydro[1,2,4]triazolo[4,3-a][1,6]naphthyridin-7(6H)-yl)-4-(2,4,5-
triﬂuorophenyl)butan-1-one Hydrochloride (43, 100% Yield). 1H
NMR (400 MHz, MeOD4) δ 7.80−7.75 (m, 1H), 7.47−7.38 (m, 1H),
7.36−7.29 (m, 1H), 7.27−7.20 (m, 1H), 6.89 (d, J = 8.1 Hz, 1H),
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5.59−5.54 (m, 1H), 4.67−4.56 (m, 1H), 4.50−4.43 (m, 1H), 4.38−
4.30 (m, 1H), 3.94−3.79 (m, 3H), 3.68−3.61 (m, 1H), 3.22−3.13 (m,
2H), 3.10−2.95 (m, 4H), 2.83−2.60 (m, 2H), 2.52−2.45 (m, 2H),
2.29−2.21 (m, 1H), 2.07−1.58 (m, 2H), 1.29 (s, 3H) ppm. HRMS m/
z: C26H30N6F3O2 calc. 515.2377 [M + H]
+, found 515.2961. HPLC
98% - method (A).
(R)-3-Amino-1-((5S*,9R*)-1-(pyridin-2-yl)-4,5,5a,8,9,9a-hexahy-
dro-[1,2,4]triazolo[4,3-a][1,6]naphthyridin-7(6H)-yl)-4-(2,4,5-
triﬂuorophenyl)butan-1-one Hydrochloride (44, 100% Yield). 1H
NMR (400 MHz, MeOD4) δ 8.81 (s, 1H), 8.26 (d, J = 7.4 Hz, 1H),
8.06 (t, J = 8.5 Hz, 1H), 7.64−7.61 (m, 1H), 7.46−7.39 (m, 1H),
7.29−7.19 (m, 1H), 5.81−5.73 (m, 1H), 4.76 (t, J = 11.9 Hz, 0.5H),
4.65 (d, J = 14.8 Hz, 0.5H), 4.32−4.21 (m, 0.5H), 4.17−4.06 (m, 1H),
3.96 (t, J = 12.9 Hz, 0.5H), 3.90−3.82 (m, 1H), 3.61−3.53 (m, 0.5H),
3.46−3.36 (m, 1H), 3.31−3.21 (m, 2H), 3.15−3.05 (m, 2H), 2.96−
2.75 (m, 2H), 2.59−2.50 (m, 1H), 2.36 (t, J = 11.9 Hz, 1H), 2.24−
2.09 (m, 1H), 2.07−1.96 (m, 1H), 1.92−1.80 (m, 1H) ppm. 13C NMR
(100 MHz, MeOD4) δ 170.4, 170.3, 170.0, 154.5, 151.5, 150.9, 146.1,
139.2, 127.4, 120.7, 107.2, 106.9, 57.2, 49.8, 45.8, 44.9, 41.3, 34.8, 34.3,
34.2, 32.4, 32.2, 29.4, 28.7, 21.4, 18.6, 18.5 ppm. HRMS m/z:
C24H26N6F3O calc. 471.2115 [M + H]
+, found 471.2754. HPLC (tR=
10.75 min, 99% - method (B)).
(R)-3-Amino-1-((5S*,9R*)-1-(pyrazin-2-yl)-4,5,5a,8,9,9a-hexahy-
dro-[1,2,4]triazolo[4,3-a][1,6]naphthyridin-7(6H)-yl)-4-(2,4,5-
triﬂuorophenyl)butan-1-one Hydrochloride (45). 1H NMR (400
MHz, MeOD4) δ 9.42 (s, 1H), 8.81 (s, 1H), 8.78 (s, 1H), 7.44−7.31
(m, 1H), 7.29−7.20 (m, 1H), 5.59−5.55 (m, 1H), 4.76 (dd, J =8.0,
13.6 Hz, 0.5H), 4.65 (dd, J =12.5 Hz, 0.5H), 4.09−4.03 (m, 0.5H),
3.96−3.80 (m, 2H), 3.28−3.16 (m, 2H), 3.13−3.01 (m, 3H), 2.88−
2.59 (m, 2H), 2.55−2.49 (m, 1H), 2.32 (t, J =12.9 Hz, 1H), 2.19−2.05
(m, 1H), 2.03−1.92 (m, 1H), 1.86−1.76 (m, 1H) ppm. 13C NMR
(100 MHz, MeOD4) δ 173.1, 170.3, 170.2, 170.0, 147.0, 145.5, 145.3,
128.4, 20.6, 120.5, 107.2, 107.0, 56.9, 49.8, 45.8, 44.9, 41.3, 34.8, 34.7,
34.5, 32.4, 29.6, 28.9, 24.2, 21.3, 19.0 ppm. HRMS m/z: C23H24N7F3O
calc. 472.2067 [M + H]+, found 472.2714. HPLC (tR= 11.87 min, 99%
- method (B)).
(R)-3-Amino-1-((5S*,9R*)-1-(2-methylthiazol-4-yl)-4,5,5a,8,9,9a-
hexahydro[1,2,4]triazolo[4,3-a][1,6]naphthyridin-7(6H)-yl)-4-(2,4,5-
triﬂuorophenyl)butan-1-one Hydrochloride (46, 68% Yield). 1H
NMR (400 MHz, MeOD4) δ 8.23−8.22 (m, 1H), 7.42−7.34 (m, 1H),
7.30−7.20 (m, 1H), 5.49−5.43 (m, 1H), 4.75 (dd, J = 8.7, 14.1 Hz,
0.5H), 4.64 (d, J = 13.0 Hz,, 0.5H), 4.06−4.00 (m, 0.5H), 3.95−3.52
(m, 1.5H), 3.59−3.52 (m, 1H), 3.29−3.19 (m, 0.5H), 3.17−3.05 (m,,
3H), 2.96−2.83 (m, 2H), 2.81 (s, 3H), 2.80−2.69 (m, 2H), 2.49 (d, J
= 13.5 Hz, 1H), 2.30−2.19 (m, 1H), 2.14−1.84 (m, 2H), 1.76 (ddd, J
= 5.8, 12.8, 25.5 Hz, 1H) ppm. 13C NMR (100 MHz, MeOD4) δ
170.3, 170.2, 169.9, 159.0, 157.0, 153.2, 153.0, 149.0, 148.7, 147.2,
141.1, 124.0, 120.6, 107.0, 56.6, 56.1, 50.2, 45.9, 44.8, 41.3, 41.2, 34.8,
34.7, 34.6, 34.5, 32.4, 32.3, 29.6, 28.9, 24.2, 21.3, 19.3 ppm. HRMS m/
z: C23H26N6F3OS calc. 491.1835 [M + H]
+, found 491.2482. HPLC
(tR= 11.94 min, 100% - method (B)).
(R)-3-Amino-1-((5R*,9R*)-1-isopropyl-4,5,5a,8,9,9a-hexahydro-
[1,2,4]triazolo[4,3-a][1,6]naphthyridin-7(6H)-yl)-4-(2,4,5-
triﬂuorophenyl)butan-1-one (47, 100% Yield). 1H NMR (400 MHz,
MeOD4) δ/ppm 7.42−7.36 (m, 1H), 7.27−7.21 (m, 1H), 4.75 (dd, J
=14.4, 15.6 Hz, 2H), 4.34−4.26 (m, 1H), 4.10−4.04 (m, 1H), 3.89−
3.82 (m, 1H), 3.51−3.43 (m, 1H), 3.27−3.21 (m, 1H), 3.16−3.02 (m,
4H), 2.96−2.64 (m, 4H), 2.13−1.74 (m, 2H), 1.44 (2d, 3H), 1.41 (2d,
3H) ppm. 13C NMR (100 MHz, MeOD4) δ 169.8 (2), 169.6, 161.1,
154.5, 120.6, 107.2, 107.0, 106.8, 61.7, 50.2, 46.1, 44.8, 41.5, 41.2, 41.0,
34.9, 34.8, 32.4, 31.4, 27.8, 23.3, 23.1, 21.2, 20.8 ppm. LC/MS m/z
436.2 [M + H]+. HPLC (tR= 7.64 min, 100% - method (B)).
4,4-Diﬂuoro-N-((S)-3-((5S*,9R*)-1-methyl-4,5,5a,8,9,9a-hexahy-
dro-[1,2 ,4]t r iazolo[4 ,3-a][1 ,6]naphthyr id in-7(6H)-y l ) -1-
phenylpropyl)cyclohexane-1-carboxamide (48). To a solution of
CBz protected amine 51a (200 mg, 0.4 mmol, 1 equiv) in methanol (7
mL) was added Pd/C and the reaction was stirred under an
atmosphere of hydrogen overnight. The crude product was ﬁltered
through Celite and the solvent was evaporated under reduced
pressure.
To 4,4-diﬂuorocyclohexane-1-carboxylic acid (38 mg, 0.2 mmol, 1.5
equiv) in DMF (3.5 mL) was added DIPEA (56 μL, 0.3 mmol, 3.0
equiv), HATU (50 mg, 0.13 mmol, 1.2 equiv) and amine (50 mg, 0.15
mmol, 1.0 equiv). The reaction was stirred at RT for 2h. and was
diluted with water (10 mL). The aqueous phase was extracted with
ethyl acetate (3 × 10 mL) and the combined organic phases were
washed with saturated aqueous ammonium chloride (10 mL), dried
over Na2SO4, ﬁltered and the solvent was evaporated under reduced
pressure. The crude product was puriﬁed by ﬂash chromatography
(dichloromethane/methanol 20:1) to yield amine 48 (68 mg, 33%) as
a white solid after further puriﬁcation using preparative HPLC.
1H NMR (400 MHz, CDCl3) δ 7.39−7.26 (m, 5H), 6.37 (dd, J =
8.2 Hz, 0.5H), 6.22 (d, J = 7.5 Hz, 0.5H), 5.15−5.05 (2q, J = 7.55 Hz;
J = 6.92 Hz, 1H), 4.02−3.96 (m, 1H), 3.26−3.16 (m, 1H), 3.12−3.09
(m, 0.5H), 3.02−2.98 (m, 0.5H), 2.94−2.91 (m, 0.5H), 2.88−2.83 (m,
1.5H), 2.42 (s, Me, 3H), 2.34−2.12 (m, 6H), 2.06−1.76 (m, 13H)
ppm. HRMS m/z C26H36F2N5O calc. 472.2882 [M + H]
+, found
472.2845. HPLC (tR 12.64 min, 100% - method (B)).
4,4-Diﬂuoro-N-((S)-3-((5R* ,9R*)-1-methyl-4,5,5a,8,9,9a-
hexahydro[1,2,4]triazolo[4,3-a][1,6]naphthyridin-7(6H)-yl)-1-
phenylpropyl)cyclohexane-1-carboxamide (49). To a solution of
CBz protected amine 51b (97 mg, 0.2 mmol, 1.0 equiv) in methanol
(1 mL) was added Pd/C and the reaction was stirred under an
atmosphere of hydrogen overnight. The crude product was ﬁltered
through Celite and the solvent was evaporated under reduced
pressure. To diﬂuorocyclohexane-1-carboxylic acid (20 mg, 0.12
mmol, 1.5 equiv) in DMF (2.5 mL) was added DIPEA (33 μL, 0.24
mmol, 3.0 equiv), HATU (37 mg, 0.1 mmol, 1.2eq) and amine (26
mg, 0.1 mmol, 1.0 equiv). The reaction was stirred at rt for 2h and was
diluted with water (10 mL). The aqueous phase was extracted with
ethyl acetate (3 × 10 mL) and the combined organic phases were
washed with saturated aqueous ammonium chloride (10 mL), dried
over Na2SO4, ﬁltered and the solvent was evaporated under reduced
pressure. The crude product was puriﬁed by ﬂash chromatography
(dichloromethane/methanol 20:1) and SCX column chromatography
(dichloromethane to methanol to 7N ammonia in methanol) to yield
amine 49 (9 mg, 24%) as a white solid after further puriﬁcation using
preparative HPLC.
1H NMR (400 MHz, CDCl3) δ 7.36−7.24 (m, 5H), 6.89−6.84 (m,
1H), 5.05 (q, J = 7.0 Hz, 1H), 3.55 (t, J = 10.8 Hz, 1H), 3.26 (d, J =
11.3 Hz, 1H), 3.20−3.15 (m, 2H), 2.92−2.83 (m, 1H), 2.68 (dt, J =
2.5, 12.6 Hz, 1H), 2.49 (d, 3H), 2.34−2.24 (m, 1H), 2.22−1.66 (m,
18H), 1.62−1.52 (m, 1H) ppm. 13C NMR (100 MHz, CDCl3) δ
173.6, 151.9, 149.9, 141.4, 128.8, 127.6, 124.4, 120.6, 58.8, 57.4, 54.5,
52.1, 42.9, 40.2, 32.9, 32.6, 32.2, 29.9, 26.0, 25.0, 22.7, 14.1. HRMS m/
z C26H36NF2O2 calc. 472.2882 [M + H]
+, found 472.2924. HPLC (tR
12.17 min, 98% - method (B)).
rel-(5R,9R)-1-Methyl-4,5,5a,6,7,8,9,9a-octahydro-[1,2,4]triazolo-
[4,3-a][1,6]naphthyridine (50). By the method outline previously, 1-
methyl-4,5,5a,6,7,8,9,9a-octahydro-[1,2,4]triazolo[4,3-a][1,6]-
naphthyridine was prepared in 76% yield. 1H NMR (400 MHz,
CDCl3) δ 3.61 (dt, J = 4.2, 11.2 Hz, 1H), 3.26 (m, 1H), 3.18−3.12 (m,
2H), 2.89−2.77 (m, 2H), 2.63−2.54 (m, 2H), 2.48 (s, 3H), 1.87−1.74
(m, 3H), 1.66 (qd, J = 3.7, 11.5 Hz, 1H), 1.50 (qd, J = 5.2, 12.6, Hz,
1H) ppm. 13C NMR (100 MHz, CDCl3) δ 152.2, 150.0, 59.9, 51.0,
45.4, 42.5, 31.9, 25.0, 23.0, 14.3 (Me) ppm. HRMS m/z: C10H17N4
calculated 193.1448 [M + H]+ found 193.1389.
Benzyl ((S)-3-((5S*,9R*)-1-Methyl-4,5,5a,8,9,9a-hexahydro[1,2,4]-
triazolo[4,3-a][1,6]naphthyridin-7(6H)-yl)-1-phenylpropyl)-
carbamate (51a). To a solution of benzyl (S)-(3-oxo-1-
phenylpropyl)carbamate (530 mg, 1.5 mmol, 1.4 equiv) in 1,2
dichloroethane (6.3 mL) was added sodium triactetoxyborohydride
(386 mg, 1.8 mmol, 1.2 equiv) and rel-(5R,9R)-1-methyl-
4,5,5a,6,7,8,9,9a-octahydro-[1,2,4]triazolo[4,3-a][1,6]naphthyridine
(50) (200 mg, 1.0 mmol, 1.7 equiv). The reaction was stirred
overnight and. the crude reaction mixture was diluted with saturated
aqueous sodium bicarbonate (25 mL). The aqueous phase was
extracted with ethyl acetate (3 × 25 mL). The combined organic
phases were dried over Na2SO4, ﬁltered and the solvent was
evaporated under reduced pressure. The crude product was puriﬁed
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.6b01801
J. Med. Chem. 2017, 60, 1534−1554
1548
by ﬂash chromatography (dichloromethane/methanol, 10:1) to give
51a (40 mg, 57%) as a colorless oil, which was further puriﬁed by
preparative HPLC.
HPLC: (tR= 15.2 min, 97%, method (B)).
1H NMR (400 MHz,
CDCl3) δ 7.37−7.22 (m, 10H), 7.13 (m, 1H), 5.16−5.03 (m, 1H),
4.96−4.83 (m, 2H), 3.97−3.91 (m, 1H), 3.11−2.53 (m, 4H), 2.40 (s,
Me, 4H), 2.39−2.19 (m, 3H), 2.11−1.69 (m, 9H) ppm. 13C NMR
(101 MHz, CDCl3) δ 156.0 (2), 150.4, 149.3, 136.6, 136.5, 128.7 (2),
127.4, 126.2, 67.7, 66.9, 66.8, 54.9, 54.4, 52.1, 42.5, 34.5, 34.0, 32.2,
21.5, 21.2, 19.7, 10.6 ppm. HRMS m/z C27H34N5O2 calc. 460.2707 [M
+ H]+, found 460.2319.
Benzyl ((S)-3-((5R*,9R*)-1-Methyl-4,5,5a,8,9,9a-hexahydro-
[1,2,4]triazolo[4,3-a][1,6]naphthyridin-7(6H)-yl)-1-phenylpropyl)-
carbamate (51b). To a solution of benzyl (S)-(3-oxo-1-
phenylpropyl)carbamate (331 mg, 0.9 mmol, 1.1 equiv) in 1,2
dichloroethane (5 mL) was added sodium triactetoxyborohydride (244
mg, 1.15 mmol), acetic acid (47 μL) and rel-(5S,9R)-1-methyl-
4,5,5a,6,7,8,9,9a-octahydro-[1,2,4]triazolo[4,3-a][1,6]naphthyridine
24 (170 mg, 0.8 mmol, 1.4 equiv) in 1,2 dichloroethane (2 mL). The
reaction was stirred overnight and the crude reaction mixture was
diluted with saturated aqueous sodium bicarbonate (10 mL). The
aqueous phase was extracted with ethyl acetate (3 × 25 mL). The
combined organic phases were dried over Na2SO4, ﬁltered and the
solvent was evaporated. The crude product was puriﬁed by ﬂash
chromatography (petrol ether/ethyl acetate, 2:1) to give the product
51b (217 mg, 57%) as colorless oil, which was further puriﬁed by
preparative HPLC.
HPLC (tR= 14.41 min, 98%, method (B)).
1H NMR (400 MHz,
CDCl3) δ 7.36−7.21 (m, 10H), 6.90−6.77 (2 x bs, 1 H), 5.17−5.06
(m, 1H), 5.01−4.93 (m, 1H), 4.90−4.81 (m, 1H), 3.49−3.17 (m, 2H),
3.15−2.86 (m, 3H), 2.78−2.67 (m, 1H), 2.52−2.46 (m, 1H), 2.44 (s,
3H), 2.41−2.30 (m, 2H), 2.14−1.99 (m, 2H), 1.93−1.69 (m, 5H),
1.55−1.42 (m, 1H) ppm.13C NMR (101 MHz, CDCl3) δ 155.9, 152.1,
149.9, 136.6, 128.5, 128.3, 127.9, 127.1, 126.1, 66.4, 59.2, 58.9, 57.8,
54.5, 52.3, 51.6, 42.4, 40.8, 40.7, 32.8, 30.5, 30.3, 24.9, 22.6, 14.0 ppm.
LCMS m/z C27H34N5O2 calc. 460.2707 [M + H]
+ found 460.2 [M +
H]+.
tert-Butyl 4-(3-Methyl-4H-1,2,4-triazol-4-yl)piperidine-1-carboxy-
late (53). Acetic hydrazide (0.814 g) was dissolved in acetonitrile (2
mL) and dimethylformamide dimethyl acetal (1.31 g) was added. The
mixture was heated to 50 °C for 30 min and then N-1 boc-4-
aminopiperidine (1.00 g) was added followed by acetic acid (1 mL).
The reaction was heated to 100 °C for 20 h and was cooled and
concentrated. The residue was partitioned between ethyl acetate (20
mL) and saturated sodium bicarbonate (20 mL) and was extracted
into ethyl acetate (2 × 20 mL). The combined extracts were dried
(MgSO4), ﬁltered and concentrated. The residue was puriﬁed by
chromatography on silica gel eluting with 0.7 N ammonia in methanol
in dichloromethane (1/9) to give the product (1.15 g, 86%) as an oil.
1H NMR (400 MHz, CDCl3) δ = 8.13 (s, 1H); 4.42−4.26 (m, 2H);
4.03−3.95 (m, 1H); 2.91−2.80 (m, 2H); 2.49 (s, 3H); 2.06−1.99 (m,
2H); 2.00 (dq, J = 4.4 and 12.3 Hz, 2H); 1.48 (s, 9H) ppm. 13C NMR
(101 MHz, CDCl3) δ = 154.4, 150.0, 140.97, 80.4, 53.45, 53.29, 32.81,
28.41, 10.73 ppm. LRMS (m/z) calcd. for C13H22N4O2 [M + H]
+
267.2, found 267.1.
tert-Butyl 4-(3-(Triﬂuoromethyl)-4H-1,2,4-triazol-4-yl)piperidine-
1-carboxylate (54, 43% Yield). 1H NMR (400 MHz, CDCl3) δ =
8.37 (s, 1H), 4.46−4.34 (m, 2H), 4.33 (tt, J 12.5 and 4.0 Hz, 1H),
2.94−2.82 (m, 2H), 2.22−2.08 (m, 2H), 1.87 (dq, J 12.5 and 4.0 Hz,
2H), 1.51 (s, 9H), LRMS (m/z): calcd. for C25H29N5O3S [M + H]
+
480.6, found 480.3.
General Procedure for Reductive Amination Reaction. A stirred
solution of 2-chloro-4-morpholinothieno[3,2-d]pyrimidine-6-carbalde-
hyde (1.1 mmol, 1.1 equiv) and corresponding substituted piperidine
(e.g., 24, 1 mmol, 1 equiv) in methanol (9 mL) and acetic acid (1 mL)
was heated to 40 °C for 1 h. and cooled to room temperature where
picoline borane (1.5 mmol, 1.5 equiv) was added and the resulting
reaction was stirred at room temperature for 20 h. The reaction
mixture was concentrated and partitioned between dichloromethane
(10 mL) and saturated sodium hydrogen carbonate (10 mL). The
mixture was extracted with dichloromethane (2 × 15 mL) and the
combined extracts were dried (MgSO4), ﬁltered and concentrated.
The residue was puriﬁed by chromatography on silica gel eluting with
2 to 10% methanol (containing 0.7N ammonia) in dichloromethane to
aﬀord the product.
4-(2-Chloro-6-((4-(3-methyl-4H-1,2,4-triazol-4-yl)piperidin-1-yl)-
methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine (56, Yield 71%). 1H
NMR (400 MHz, DMSO) δ 8.61 (s, 1H), 7.33 (s, 1H), 4.07−3.94 (m,
1H), 3.96−3.87 (m, 6H), 3.81−3.73 (m, 4H), 3.06−2.99 (m, 2H),
2.38 (s, 3H), 2.31−2.26 (m, 2H), 1.97−1.84 (m, 4H), LRMS (m/z)
calcd. for C19H24ClN7OS [M + H]
+ 434.0, found 434.4.
4-(2-Chloro-6-((4-(3-(triﬂuoromethyl)-4H-1,2,4-triazol-4-yl)-
piperidin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine (57,
Yield 30%). 1H NMR (400 MHz, DMSO) δ 9.26 (s, 1H), 7.32 (s,
1H), 4.26−4.13 (m, 1H), 3.93 (s, 2H), 3.92−3.87 (m, 4H), 3.81−3.74
(m, 4H), 3.08−3.00 (m, 2H), 2.31 (td, J = 2.5, 11.8 Hz, 2H), 2.09 (qd,
J = 3.6, 12.0 Hz, 2H), 2.04−1.96 (m, 2H). 13C NMR (101 MHz,
DMSO) δ 163.0, 158.4, 156.3, 152.9, 145.8, 142.6, 122.4, 117.9, 112.7,
66.3, 56.4, 54.9, 52.2, 46.4, 39.9, 32.8. LRMS (m/z): calcd. for
C19H21ClF3N7OS [M + H]+ 488.9, found 488.3.
rel-4-(2-Chloro-6-(((5S,9R)-1-methyl-4,5,5a,8,9,9a-hexahydro-
[1,2,4]triazolo[4,3-a][1,6]naphthyridin-7(6H)-yl)methyl)thieno[3,2-
d]pyrimidin-4-yl)morpholine (58, Yield 49%). 1H NMR (400 MHz,
CDCl3) δ 7.21 (s, 1H), 4.15 (dt, J = 5.1 and 11.6 Hz, 1H), 4.06−3.98
(m, 4H), 3.91−3.79 (m, 6H), 3.30 (dd, J = 5.6 and 17.5 Hz, 1H),
3.11−3.03 (m, 2H), 2.95−2.85 (m, 1H), 2.57−2.43 (m, 2H), 2.51 (s,
3H), 2.32−2.26 (m, 2H), 2.05−1.97 (m, 1H), 1.96−1.87 (m, 2H)
ppm. LRMS (m/z) calcd. for C21H26ClN7OS [M + H]
+ 460.2, found
460.4.
rel-4-(2-Chloro-6-(((5S,9R)-1-(triﬂuoromethyl)-4,5,5a,8,9,9a-
hexahydro[1,2,4]triazolo[4,3-a][1,6]naphthyridin-7(6H)-yl)methyl)-
thieno[3,2-d]pyrimidin-4-yl)morpholine (59, Yield 91%). 1H NMR
(400 MHz, CDCl3) δ 7.34 (s, 1H), 4.53−4.43 (m, 1H), 4.08−3.99 (m,
4H), 3.91−3.85 (m, 6H), 3.42−3.33 (m, 1H), 3.31−3.18 (m, 1H),
3.04−2.91 (m, 1H), 2.84−2.66 (m, 2H), 2.44−2.34 (m, 2H), 2.28−
2.21 (m, 2H), 2.03−1.97 (m, 2H) ppm. LRMS (m/z) calcd. for
C21H23ClF3N7OS [M + H]
+ 514.13, found 514.2
rel-4-(2-Chloro-6-(((5R,9R)-1-methyl-4,5,5a,8,9,9a-hexahydro-
[1,2,4]triazolo[4,3-a][1,6]naphthyridin-7(6H)-yl)methyl)thieno[3,2-
d]pyrimidin-4-yl)morpholine (60, Yield 54%). 1H NMR (400 MHz,
DMSO) δ 7.32 (s, 1H), 4.20−3.62 (m, 10H), 2.98−2.86 (m, 3H),
2.64−2.55 (m, 3H), 2.40 (s, 3H), 1.79−1.63 (m, 2H), 1.58−1.43 (m,
4H), LRMS (m/z) calcd. for C21H26ClN7OS [M + H]
+ 460.5, found
460.3
rel-4-(2-Chloro-6-(((5R,9R)-1-(triﬂuoromethyl)-4,5,5a,8,9,9a-hex-
ahydro-[1,2,4]triazolo[4,3-a][1,6]naphthyridin-7(6H)-yl)methyl)-
thieno[3,2-d]pyrimidin-4-yl)morpholine (61, Yield 62%). 1H NMR
(400 MHz, DMSO) δ 7.32 (s, 1H), 4.03−3.85 (m, 7H), 3.78−3.72
(m, 4H), 3.15−3.00 (m, 3H), 3.02−2.88 (m, 1H), 2.41−2.29 (m, 2H),
2.20−1.98 (m, 2H), 1.95−1.73 (m, 2H), 1.67−1.52 (m, 1H), LRMS
(m/z) calcd. for C21H23ClF3N7OS [M + H]
+ 514.5, found 514.4
General Procedure for Suzuki Reaction. A mixture of the
chlorinated pyrimidine (56-61) (0.17 mmol, 1 equiv), aryl boronic
acid (40), (0.25 mmol, 1.5 equiv), aqueous 2 M Na2CO3 (0.51 mmol,
3 equiv) and bis(triphenylphosphine) palladium chloride (0.017 mmol,
0.1 equiv) in EtOH: deionized water, (3 mL, 3:1) was irradiated under
microwave radiation for 45 min at 125 °C. After concentration the
residue was puriﬁed by ﬂash column chromatography (silica gel),
eluting with 0−10% MeOH in CH2Cl2 containing NH3 (0.7 N) to give
the product.
3-(6-((4-(3-Methyl-4H-1,2,4-triazol-4-yl)piperidin-1-yl)methyl)-4-
morpholinothieno[3,2-d]pyrimidin-2-yl)phenol (62, Yield 54%). 1H
NMR (400 MHz, DMSO) δ 9.51 (s, 1H), 8.62 (s, 1H), 7.89−7.82 (m,
2H), 7.41 (s, 1H), 7.28 (t, J = 8.0 Hz, 1H), 6.91−6.83 (m, 1H), 4.03−
3.96 (m, 5H), 3.94 (s, 2H), 3.86−3.79 (m, 4H), 3.09−3.01 (m, 2H),
2.38 (s, 3H), 2.31−2.26 (m, 2H), 1.98−1.89 (m, 4H). 13C NMR (101
MHz, DMSO) δ 162.7, 159.6, 157.9, 157.9, 150.9, 150.1, 141.7, 139.9,
129.7, 123.6, 119.0, 117.5, 114.9, 112.7, 66.5, 56.8, 52.5, 52.4, 46.3,
32.5, 10.5. LRMS (tR= 1.98 min, 99% - method (A)), (m/z) calcd. for
C25H29N7O2S [M + H]
+ 492.2, found 492.4.
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4-(2-(1H-Indazol-4-yl)-6-((4-(3-methyl-4H-1,2,4-triazol-4-yl)-
piperidin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine (63,
Yield 54%). 1H NMR (400 MHz, DMSO) δ 13.21 (s, 1H), 8.91 (s,
1H), 8.62 (s, 1H), 8.25 (d, J = 7.2 Hz, 1H), 7.68 (d, J = 8.2 Hz, 1H),
7.54 (s, 1H), 7.49 (t, J = 7.8 Hz, 1H), 4.07−4.00 (m, 5H), 3.97 (s,
2H), 3.90−3.82 (m, 4H), 3.11−3.02 (m, 2H), 2.38 (s, 3H), 2.35−2.22
(m, 2H), 2.01−1.88 (m, 4H). 13C NMR (101 MHz, DMSO) δ 162.7,
160.1, 158.1, 151.0, 150.1, 141.7, 141.3, 135.6, 131.6, 126.1, 123.9,
121.7, 121.5, 112.8, 112.6, 66.5, 56.8, 52.5, 52.4, 46.6, 32.6, 10.5.
LRMS (tR= 1.99 min, 99% - method (A)), (m/z) calcd. for
C26H29N9OS [M + H]
+ 516.2, found 516.5.
4-(2-(1H-Indol-4-yl)-6-((4-(3-methyl-4H-1,2,4-triazol-4-yl)-
piperidin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine (64,
Yield 64%). 1H NMR (400 MHz, DMSO) δ 11.25 (s, 1H), 8.63 (s,
1H), 8.18−8.12 (m, 1H), 7.61−7.40 (m, 3H), 7.26−7.18 (m, 1H),
4.04−3.99 (m, 5H), 3.99−3.94 (m, 2H), 3.92−3.79 (m, 4H), 3.07 (d, J
= 11.2 Hz, 2H), 2.39 (s, 3H), 2.30 (s, 2H), 1.95 (s, 4H). 13C NMR
(101 MHz, DMSO) δ 162.8, 161.7, 158.0, 150.5, 150.1, 141.7, 137.5,
130.2, 126.8, 126.4, 123.9, 120.9, 113.8, 112.1, 103.9, 66.5, 56.8, 52.5,
52.4, 46.6, 32.6, 10.5. LRMS (tR= 2.07 min, 99% - method (A)), (m/z)
calcd. for C27H30N8O2S [M + H]
+ 515.2, found 515.3.
3-(4-Morpholino-6-((4-(3-(triﬂuoromethyl)-4H-1,2,4-triazol-4-yl)-
piperidin-1-yl)methyl)thieno[3,2-d]pyrimidin-2-yl)phenol (65, 89%
Yield). 1H NMR (400 MHz, DMSO) δ 9.50 (s, 1H), 9.27 (s, 1H), 7.85
(d, J = 7.1 Hz, 2H), 7.41 (s, 1H), 7.28 (t, J = 8.0 Hz, 1H), 6.90−6.83
(m, 1H), 4.23−4.18 (m, 1H), 4.02−3.97 (m, 4H), 3.96−3.92 (m, 2H),
3.86−3.79 (m, 4H), 3.11−3.03 (m, 2H), 2.31 (t, J = 11.6 Hz, 2H),
2.12 (dt, J = 6.7, 12.4 Hz, 2H), 2.05−2.00 (m, 2H). 13C NMR (101
MHz, DMSO) δ 162.7, 159.6, 157.9, 150.9, 145.8, 139.9, 129.7, 123.6,
66.5, 56.6, 55.0, 52.2, 46.3, 32.8. LRMS (tR= 2.18 min, 99% - method
(A)), (m/z): calcd. for C25H26F3N7O2S [M + H]
+ 546.6, found 546.4.
4-(2-(1H-Indazol-4-yl)-6-((4-(3-(triﬂuoromethyl)-4H-1,2,4-triazol-
4-yl)piperidin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine
(66, 86% Yield). 1H NMR (400 MHz, DMSO) δ 13.21 (s, 1H), 9.28
(s, 1H), 8.90 (s, 1H), 8.24 (d, J = 7.3 Hz, 1H), 7.68 (d, J = 8.3 Hz,
1H), 7.53 (s, 1H), 7.48 (t, J = 7.8 Hz, 1H), 4.27−4.19 (m, 1H), 4.03
(t, J = 4.7 Hz, 4H), 3.99−3.94 (m, 2H), 3.90−3.82 (m, 4H), 3.10 (d, J
= 11.4 Hz, 2H), 2.33 (t, J = 11.5 Hz, 2H), 2.17−2.09 (m, 2H), 2.07−
2.02 (m, 2H). LRMS (tR= 2.25 min, 97% - method (A)), (m/z): calcd.
for C27H27F3N8OS [M + H]
+ 569.6, found 569.4.
4-(2-(1H-Indol-4-yl)-6-((4-(3-methyl-4H-1,2,4-triazol-4-yl)-
piperidin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine (67,
97% Yield). 1H NMR (400 MHz, DMSO) δ 11.24 (s, 1H), 9.28 (s,
1H), 8.14 (d, J = 7.5 Hz, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.49−7.43 (m,
3H), 7.21 (t, J = 7.7 Hz, 1H), 4.26−4.15 (m, 1H), 4.05−3.99 (m, 4H),
3.98−3.93 (m, 2H), 3.88−3.81 (m, 4H), 3.16−3.05 (m, 2H), 2.32 (t, J
= 11.5 Hz, 2H), 2.19−2.05 (m, 2H), 2.06−2.01 (m, 2H). 13C NMR
(101 MHz, DMSO) δ 162.8, 161.8, 158.0, 150.6, 145.8, 142.8 (q, J =
76.9 Hz), 137.5, 130.2, 126.8, 126.4, 123.9, 120.9, 119.2 (q, J = 269.3,
297.5 Hz), 113.8, 112.1, 103.9, 66.5, 56.6, 55.0, 52.2, 46.5, 32.9. LRMS
(tR= 2.19 min, 99% - method (A)), (m/z): calcd. for C27H27F3N8OS
[M + H]+ 569.6, found 569.4.
rel-4-(2-(1H-Indazol-4-yl)-6-(((5S,9R)-1-(triﬂuoromethyl)-
4,5,5a,8,9,9a-hexahydro[1,2,4]triazolo[4,3-a][1,6]naphthyridin-
7(6H)-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine (68, 65%
Yield). 1H NMR (400 MHz, d6-DMSO) δ = 13.21 (s, 1H), 8.90 (s,
1H), 8.24 (d, J = 7 Hz, 1H), 7.68 (d, J = 8.1 Hz, 1H), 7.51 (s, 1H),
7.49 (t, J = 7.8 Hz, 1H), 4.51−4.46 (m, 1H), 4.06−3.99 (m, 4H), 3.90
(q, J = 15 Hz, 2H), 3.89−3.82 (m, 4H), 3.17 (dd, J = 16 and 5.9 Hz,
1H), 3.05−2.97 (m, 2H), 2.94−2.85 (m, 1H), 2.50−2.41 9m, 1H),
2.36−2.24 (m, 2H), 2.08−1.92 (m, 2H), 1.87−1.79 (m, 1H) ppm. 13C
NMR (101 MHz, d6-DMSO) δ 162.8, 160.1, 158.1, 154.2, 151.3, 142.2
(d, JC−F = 38.5 Hz), 141.2, 135.6, 131.6, 126.1, 123.6, 121.6, 121.5,
119.3 (d, JC−F = 269 Hz), 112.8, 112.5, 66.5, 56.8, 56.6, 54.2, 52.1,
46.6, 33.6, 29.6, 21.3, 20.1 ppm. LRMS (tR= 2.40 min, 98% - method
(A)), (m/z) calcd. for C28H28F3N9OS [M + H]
+ 596.65, found 596.4.
rel-3-(4-Morpholino-6-(((5S,9R)-1-(triﬂuoromethyl)-4,5,5a,8,9,9a-
hexahydro[1,2,4]triazolo[4,3-a][1,6]naphthyridin-7(6H)-yl)methyl)-
thieno[3,2-d]pyrimidin-2-yl)phenol (69, 72% Yield). 1H NMR (400
MHz, DMSO) δ = 9.49 (s, 1H), 7.87−7.83 (m, 2H), 7.39 (s, 1H),
7.28 (t, J = 8.2 Hz), 6.87 (d, J = 9 Hz, 1H), 4.51−4.45 (m, 1H), 4.07−
3.96 (m, 4H), 3.87 (q, J = 15 Hz, 2H), 3.85−3.79 (m, 4H), 3.21−3.13
(m, 1H), 3.02−2.96 (m, 2H), 2.94−2.85 (m, 1H), 2.50−2.40 (m, 1H),
2.35−2.23 (m, 2H), 2.07−1.91 (m, 2H), 1.85−1.78 (m, 1H) ppm. 13C
NMR (101 MHz, d6-DMSO) δ 162.8, 159.5, 157.9, 154.2, 151.2, 142.2
(d, JC−F = 38.5 Hz), 139.9, 129.7, 123.3, 119.3 (d, JC−F = 269 Hz),
119.0, 118.0, 117.5, 114.9, 112.7, 66.5, 56.8, 56.6, 54.2, 52.1, 46.4, 33.5,
29.6, 21.3, 20.1 ppm. LRMS (tR= 2.36 min, 98% - method (A)), (m/z)
calcd. for C27H28F3N7O2S [M + H]
+ 572.2, found 572.2.
rel-3-(6-(((5S,9R)-1-Methyl-4,5,5a,8,9,9a-hexahydro[1,2,4]-
t r i a zo lo [4 , 3 -a ] [ 1 , 6 ]naphthy r id in -7 (6H ) - y l )me thy l ) - 4 -
morpholinothieno[3,2-d]pyrimidin-2-yl)phenol (70, 95% Yield). 1H
NMR (400 MHz, DMSO) δ = 9.52 (s, 1H), 7.85−7.84 (m, 2H), 7.38
(s, 1H), 7.28 (t, J = 7.7 Hz, 1H), 6.87 (d, J = 7.7 Hz, 1H), 4.24−4.16
(m, 1H), 4.05−3.96 (m, 4H), 3.87 (q, J = 15 Hz, 2H), 3.84−3.79 (m,
4H), 3.03−2.92 (m, 3H), 2.74−2.63 (m, 1H), 2.44−2.39 (m, 1H),
2.38−2.28 (m, 1H), 2.32 (s, 3H), 2.34 (t, J = 12 Hz, 1H), 2.19−2.11
(m, 1H), 1.99−1.93 (m, 1H), 1.79−1.65 (m, 2H) ppm. 13C NMR
(101 MHz, d6-DMSO) δ 162.8, 159.5, 157.9 (2 x C), 151.4, 149.9,
149.2, 140.0, 129.8, 123.3, 119.1, 117.6, 115.0, 112.7, 66.5, 57.2, 57.0,
52.3, 51.3, 46.4, 34.2, 28.9, 21.5, 21.0, 10.4 ppm. LRMS (tR= 2.02 min,
99% - method (A)), (m/z) calcd. for C27H31N7O2S [M + H]
+ 518.65,
found 518.5.
rel-4-(2-(1H-Indazol-4-yl)-6-(((5S,9R)-1-methyl-4,5,5a,8,9,9a-
hexahydro[1,2,4]triazolo[4,3-a][1,6]naphthyridin-7(6H)-yl)methyl)-
thieno[3,2-d]pyrimidin-4-yl)morpholine (71, 68% Yield). 1H NMR
(400 MHz, DMSO) δ = 13.22 (s, 1H), 8.90 (s, 1H), 8.24 (d, J = 7.3
Hz, 1H), 7.68 (d, J= 7.7 Hz, 1H), 7.52−7.46 (m, 2H), 4.25−4.18 (m,
1H), 4.06−4.0 (m, 4H), 3.90 (q, J = 15 Hz, 2H), 3.89−3.82 (m, 4H),
3.05−2.93 (m, 3H), 2.75−2.64 (m, 1H), 2.47−2.41 (m, 1H), 2.38−
2.28 (m, 1H), 2.32 (s, 3H), 2.25 (t, J = 11 Hz, 1H), 2.19−2.11 (m,
1H), 2.01−1.94 (m, 1H), 1.80−1.66 (m, 2H) ppm. 13C NMR (101
MHz, d6-DMSO) δ 162.8, 160.1, 158.1, 151.4, 149.9, 149.1, 141.3,
135.6, 131.6, 126.1, 123.5, 121.6, 121.5, 112.8, 112.5, 66.5, 57.2, 57.0,
52.3, 51.3, 46.6, 34.2, 28.9, 21.5, 20.9, 10.4 ppm. LRMS (m/z) (tR=
2.04 min, 98% - method (A)), calcd. for C27H31N9OS [M + H]
+
542.68, found 542.4.
rel-4-(2-(1H-Indol-4-yl)-6-(((5S,9R)-1-(tr iﬂuoromethyl)-
4,5,5a,8,9,9a-hexahydro[1,2,4]triazolo[4,3-a][1,6]naphthyridin-
7(6H)-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine (72, 62%
Yield). 1H NMR (400 MHz, DMSO) δ 11.24 (s, 1H), 8.14 (d, J =
7.4 Hz, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.46 (s, 3H), 7.21 (t, J = 7.8 Hz,
1H), 5.77 (s, 1H), 4.03−3.96 (m, 4H), 3.87−3.79 (m, 4H), 3.34 (s,
1H), 3.19−3.02 (m, 3H), 2.95 (ddd, J = 6.2, 11.4, 17.3 Hz, 1H), 2.41−
2.29 (m, 2H), 2.18−2.02 (m, 2H), 1.92−1.74 (m, 2H), 1.59 (tt, J =
6.7, 13.5 Hz, 1H). 13C NMR (101 MHz, DMSO) δ 162.8, 161.7,
158.0, 156.1, 150.4, 137.5, 130.2, 126.8, 126.4, 123.9, 120.9, 113.8,
112.1, 110.0, 103.9, 66.5, 60.5, 57.0, 56.4, 55.4, 51.9, 46.5, 30.5, 23.4,
22.7. LRMS (tR= 2.33 min, 97% - method (A)), (m/z): calcd. for
C29H29F3N8OS [M + H]
+ 595.7, found 595.5.
rel-4-(2-(1H-Indol-4-yl)-6-(((5S,9R)-1-methyl-4,5,5a,8,9,9a-
hexahydro[1,2,4]triazolo[4,3-a][1,6]naphthyridin-7(6H)-yl)methyl)-
thieno[3,2-d]pyrimidin-4-yl)morpholine (73, 60% Yield). 1H NMR
(400 MHz, DMSO) δ = 11.24 (s, 1H), 8.14 (d, J = 7.0 Hz, 1H), 7.53
(d, J = 8.1 Hz, 1H), 7.47−7.43 (m, 3H), 7.21 (t, J = 8.1 Hz), 4.21−
4.17 (m, 1H), 4.0−4.0 (m, 4H), 3.88 (q, J = 15 Hz, 2H) 3.87−3.81
(m, 4H), 3.04−2.93 (m, 3H), 2.74−2.64 (m, 1H), 2.45−2.39 (m, 1H),
2.37−2.29 (m, 1H), 2.32 (s, 3H), 2.24 (t, J = 10.9 Hz, 1H), 2.17−2.11
(m, 1H), 2.01−1.94 (m, 1H), 1.79−1.65 (m, 2H) ppm. 13C NMR
(101 MHz, d6-DMSO) δ 162.9, 161.7, 158.0, 150.9, 149.9, 149.1,
137.5, 130.2, 126.8, 126.4, 123.6, 120.9, 120.8, 113.8, 112.1, 103.8,
66.5, 65.4, 57.1, 57.0, 52.2, 51.4, 46.6, 34.1, 28.9, 21.5, 21.0, 10.4 ppm.
LRMS (tR= 2.03 min, 98% - method (A)), (m/z) calcd. for
C29H32N8OS [M + H]
+ 541.69, found 541.3.
rel-4-(2-(1H-Indazol-4-yl)-6-(((5R,9R)-1-(triﬂuoromethyl)-
4,5,5a,8,9,9ahexahydro[1,2,4]triazolo[4,3-a][1,6]naphthyridin-
7(6H)-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine (74, 78%
Yield). 1H NMR (400 MHz, DMSO) δ 11.24 (s, 1H), 8.14 (d, J =
7.4 Hz, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.48−7.43 (m, 3H), 7.21 (t, J =
7.8 Hz, 1H), 5.77 (s, 1H), 4.03−3.96 (m, 4H), 3.97−3.91 (m, 2H),
3.87−3.79 (m, 4H), 3.19−3.06 (m, 2H), 3.08−2.91 (m, 2H), 2.35 (t, J
= 12.2 Hz, 2H), 2.10 (p, J = 11.1 Hz, 2H), 1.83 (ddt, J = 7.3, 13.8, 27.0
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Hz, 2H), 1.59 (tt, J = 6.7, 13.5 Hz, 1H). LRMS (tR= 2.28 min, 99% -
method (A)), (m/z): calcd. for C27H28F3N7O2S [M + H]
+ 572.6,
found 572.4.
rel-3-(4-Morpholino-6-(((5R,9R)-1-(triﬂuoromethyl)-4,5,5a,8,9,9a-
hexahydro[1,2,4]triazolo[4,3-a][1,6]naphthyridin-7(6H)-yl)methyl)-
thieno[3,2-d]pyrimidin-2-yl)phenol (75, 74% Yield). 1H NMR (400
MHz, DMSO) δ 9.50 (s, 1H), 7.89−7.82 (m, 2H), 7.40 (s, 1H), 7.28
(t, J = 8.0 Hz, 1H), 6.91−6.83 (m, 1H), 4.01−3.95 (m, 5H), 3.93 (s,
2H), 3.81 (t, J = 4.7 Hz, 4H), 3.18−3.02 (m, 3H), 2.95 (td, J = 5.9,
14.5, 16.9 Hz, 1H), 2.37 (d, J = 12.1 Hz, 2H), 2.19−2.02 (m, 2H),
1.81 (ddd, J = 4.6, 12.3, 24.5 Hz, 2H), 1.60 (tt, J = 6.5, 13.6 Hz, 1H).
13C NMR (101 MHz, DMSO) 162.7, 159.5, 157.9, 157.9, 156.1, 150.8,
139.9, 129.7, 123.6, 119.0, 117.5, 114.9, 112.7, 66.5, 60.5, 57.0, 56.4,
51.9, 46.3, 39.5, 30.5, 23.4, 22.7. LRMS (tR= 2.23 min, 99% - method
(A)), (m/z): calcd. for C27H28F3N7O2S [M + H]
+ 572.6, found 572.4.
rel-4-(2-(1H-Indazol-4-yl)-6-(((5R,9R)-1-methyl-4,5,5a,8,9,9a-
hexahydro[1,2,4]triazolo[4,3-a][1,6]naphthyridin-7(6H)-yl)methyl)-
thieno[3,2-d]pyrimidin-4-yl)morpholine (76, 64% Yield). 1H NMR
(400 MHz, DMSO) δ 13.21 (s, 1H), 8.91 (s, 1H), 8.25 (d, J = 7.2 Hz,
1H), 7.68 (d, J = 8.3 Hz, 1H), 7.54 (s, 1H), 7.49 (t, J = 7.8 Hz, 1H),
4.06−3.91 (m, 5H), 3.88−3.81 (m, 4H), 3.72 (td, J = 3.7, 11.1 Hz,
1H), 3.10 (dd, J = 11.3, 24.6 Hz, 2H), 2.92 (dd, J = 5.0, 15.9 Hz, 2H),
2.87−2.73 (m, 1H), 2.63−2.58 (m, 1H), 2.42 (s, 3H), 2.39−2.31 (m,
1H), 2.12 (t, J = 11.0 Hz, 1H), 1.99−1.85 (m, 1H), 1.83−1.66 (m,
2H), 1.58−1.43 (m, 1H). LRMS (tR= 2.01 min, 99% - method (A)),
(m/z) calcd. for C28H31N9OS [M + H]
+ 542.2, found 542.3.
rel-4-(2-(1H-Indol-4-yl)-6-(((5R,9R)-1-(triﬂuoromethyl)-
4,5,5a,8,9,9a-hexahydro-[1,2,4]triazolo[4,3-a][1,6]naphthyridin-
7(6H)-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine (77, 81%
Yield). 1H NMR (400 MHz, DMSO) δ 11.24 (s, 1H), 8.14 (d, J =
7.4 Hz, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.48−7.43 (m, 3H), 7.21 (t, J =
7.8 Hz, 1H), 5.77 (s, 1H), 4.03−3.96 (m, 4H), 3.97−3.91 (m, 2H),
3.87−3.79 (m, 4H), 3.19−3.06 (m, 2H), 3.08−2.91 (m, 2H), 2.35 (t, J
= 12.2 Hz, 2H), 2.10 (p, J = 11.1 Hz, 2H), 1.83 (ddt, J = 7.3, 13.8, 27.0
Hz, 2H), 1.59 (tt, J = 6.7, 13.5 Hz, 1H). LRMS (tR= 2.22 min, 99% -
method (A)), (m/z): calcd. for C27H28F3N7O2S [M + H]
+ 572.6,
found 572.4.
rel-4-(2-(1H-Indol-4-yl)-6-(((5R,9R)-1-methyl-4,5,5a,8,9,9a-
hexahydro[1,2,4]triazolo[4,3-a][1,6]naphthyridin-7(6H)-yl)methyl)-
thieno[3,2-d]pyrimidin-4-yl)morpholine (78, Yield 58%). 1H NMR
(400 MHz, DMSO) δ 11.25 (s, 1H), 8.18−8.11 (m, 1H), 7.58−7.51
(m, 1H), 7.50−7.43 (m, 3H), 7.26−7.17 (m, 1H), 4.03−3.94 (m, 6H),
3.88−3.81 (m, 4H), 3.76−3.68 (m, 1H), 3.17−3.02 (m, 2H), 2.97−
2.88 (m, 1H), 2.83−2.78 (m, 2H), 2.73−2.57 (m, 1H), 2.42 (s, 3H),
2.38−2.33 (m, 1H), 2.16−2.06 (m, 1H), 1.95−1.88 (m, 1H), 1.84−
1.65 (m, 1H), 1.55−1.50 (m, 1H). 13C NMR (101 MHz, DMSO) δ
162.8, 161.7, 158.0, 151.9, 149.8, 137.5, 130.1, 126.8, 126.4, 123.9,
120.9, 113.8, 112.1, 103.9, 66.5, 58.7, 57.2, 56.6, 52.0, 46.6, 40.7, 40.5,
30.2, 24.8, 22.6, 13.9. LRMS (tR= 2.05 min, 99% - method (A)), (m/z)
calcd. for C29H32N8OS [M + H]
+ 541.2, found 541.4.
rel-3-(6-(((5R,9R)-1-Methyl-4,5,5a,8,9,9a-hexahydro-[1,2,4]-
t r i a zo lo [ 4 , 3 -a ] [ 1 , 6 ]naphthy r i d in -7 (6H ) - y l )me thy l ) - 4 -
morpholinothieno[3,2-d]pyrimidin-2-yl)phenol (79, Yield 59%). 1H
NMR (400 MHz, DMSO) δ 9.99−9.42 (m, 1H), 8.11 (s, 1H), 7.94−
7.84 (m, 2H), 7.36 (t, J = 7.9 Hz, 1H), 7.05−6.98 (m, 1H), 4.97−4.64
(m, 2H), 4.33−4.20 (m, 1H), 4.15−4.08 (m, 4H), 3.90−3.83 (m, 4H),
3.80−2.75 (m, 8H), 2.70 (s, 3H), 2.43−1.88 (m, 2H), 1.76−1.55 (m,
1H). LRMS (tR = 1.97 min, 99% - method (A)), (m/z) calcd. for
C27H31N7O2S [M + H]
+ 518.2, found 518.6.
PharmacologyGeneral Methods. DPP-4 Biochemical Assay:63
Enzyme: DPP4 recombinant human protein was purchased from Sino
Biological Inc. Substrate: H-Gly-Pro-AMC was purchased from
Bachem Americas, Inc. Assay buﬀer (100 mM Hepes, pH 7.5) was
prepared by HitGen. All chemical reagents used were of analytical
reagent grade. Assay protocol: Prepare 10 mM compound stock
solution in DMSO. The initial rate of DPP4 activity is measured over
15 min by monitoring the ﬂuorescent change (ex/em =360/460 nm).
The ﬁts are inspected to ensure that the reactions are linear to a
correlation coeﬃcient of 0.9. IC50 values are calculated by ﬁtting
percent remaining activity vs log (inhibitor concentration) using four-
parameter dose−response model (Sigmaplot Version 11.0).
CCR5 Receptor Antagonism Assay. The transfection for the
generation of the HEK 293 Glosensor cells stably expressing CCR-5
was carried out using CCR-5 plasmid obtained from the cDNA.org
library (CCR050TN00) and Lipofectamine according to the
manufacturers’ instructions. Transfected cells were subjected to
selective pressure for 2−3 weeks through the addition of 1 mg.mL−1
G418.HEK 293 Glosensor cells expressing CCR-5 with a density of 2.5
× 104 cells/mL were placed in each well of a 96 well black plate (100
μL) were incubated at 37 °C, 5% CO2 for 48 h prior to the assay. On
the day of experiment the medium was aspirated and replaced with
assay buﬀer prepared by adding glucose (90 mg) and BSA (50 mg) to
50 mL 1 x HBSS and probenecid solution (180 mg probenecid, 1.25
mL 1 M NaOH and 1.25 mL assay buﬀer, 500 μL) (complete assay
buﬀer). The complete assay buﬀer (10 mL) was supplemented by 23
μL Fluo-4 dye (prepared by adding 23 μL DMSO and 23 μL pluronic
acid 20% in DMSO to Fluo-4 AM) (Fluo-4 buﬀer). Fluo-4 buﬀer (100
μL) was added to each well of the black walled plate and incubated at
37 °C for 45 min. Antagonist (compound) solutions were prepared by
either a single concentration (300 nM (48) or 10 μM (49) in
complete assay buﬀer) The Fluo-4 buﬀer was aspirated and the cells
were washed (x2) with complete assay buﬀer. Complete assay buﬀer
(100 μL) was added to the wells and 10 μL of the corresponding
concentration of the antagonist was added in triplicate and incubated
for 30 min at 37 °C to give ﬁnal concentrations of 30 nM or 1 μM.
Agonist concentrations for the dose response curve were prepared as
serial dilutions with ﬁnal concentrations of 100 nM −1 nM in half logs
(RANTES). Agonist concentrations (20 μL) were added in triplicate
into a clear 96 well plate and were added directly prior to the
measurement. The wells were screened on the Flexstation 1
(Molecular Devices) by measuring intracellular calcium by monitoring
the change in ﬂuorescence every 2s for 5 min. The estimated aﬃnity
value for each antagonist (pKD) was calculated from the shift of the
agonist dose response curve brought about by addition of a single
concentration of antagonist (30 nM or 1 μM) using the Gaddum
equation as previously described.40
PI3K Inhibition Assay. Inhibition of PI3K α, -β, -γ, and -δ enzymatic
activity was determined using a homogeneous time-resolved
ﬂuorescence (HTRF) kit assay format provided by Millipore.54
Molecular DockingGeneral Methods. The three-dimensional
coordinates of the cocrystal structure of sitagliptin in the active site of
DPP4 (pdb code 1 × 70), the cocrystal structure of maraviroc in the
active site of the chemokine receptor CCR-5 (pdb code 4MBS) and
the crystal structure of PI3K δ in complex with pictilisib (pdb code
2WXP) were retrieved from the Protein Data Bank.64 All nonprotein
atoms, including water and sugar molecules were removed from the
model. Using MAKE RECEPTOR 3.0.0 software (OpenEye Scientiﬁc
Software) an active site model was prepared for each active site (DPP-
4, CCR5, PI3K δ) being considered. No constraints were used during
this preparation of the receptor model. A database composed of
suggested compounds for docking and the reference ligands
[sitagliptin (DPP-4), maraviroc (CCR5), pictilisib (PI3K δ)] and
the newly designed compounds were processed with the Omega
2.5.1.4 software (OpenEye Scientiﬁc Software, Inc.,) to generate the
200 lowest energy conformations for each compound. Finally, the
compounds were docked into the active site models using the FRED
3.0.1 software and the Chemgauss4 scoring function (OpenEye
Scientiﬁc Software, Inc.,). The docking was visually analyzed for the
top 5 best scored poses for the conformation of the designed
compounds using VIDA 4.3.0 and outputs visualized using PyMOL
(The PyMOL Molecular Graphics System, Version 1.8 Schrödinger,
LLC). The poses were visually compared with the cocrystallized
reference ligand and the best overlaying docking pose has been
presented in this manuscript.
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McLean, N.; Mörtl, M.; Nonomiya, J.; Pang, J.; Price, S.; Prior, W. W.;
Salphati, L.; Sideris, S.; Staben, S. T.; Steinbacher, S.; Tsui, V.; Wallin,
J.; Sampath, D.; Olivero, A. G. The Rational Design of Selective
Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-
Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1 H
−1,2,4-Triazol-5-Yl)-5,6-Dihydrobenzo[ F ]imidazo[1,2- D ][1,4]-
oxazepin-9-Yl)oxy)propa. J. Med. Chem. 2016, 59 (3), 985−1002.
(51) Sato, S.; Sakamoto, T.; Miyazawa, E.; Kikugawa, Y. One-Pot
Reductive Amination of Aldehydes and Ketones with α-Picoline-
Borane in Methanol, in Water, and in Neat Conditions. Tetrahedron
2004, 60 (36), 7899−7906.
(52) Miyaura, N.; Yamada, K.; Suzuki, A. A New Stereospecific
Cross-Coupling by the Palladium-Catalyzed Reaction of 1-Alkenylbor-
anes with 1-Alkenyl or 1-Alkynyl Halides. Tetrahedron Lett. 1979, 20
(36), 3437−3440.
(53) Miyaura, N.; Suzuki, A. Stereoselective Synthesis of Arylated
(E)-Alkenes by the Reaction of Alk-1-Enylboranes with Aryl Halides in
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.6b01801
J. Med. Chem. 2017, 60, 1534−1554
1553
the Presence of Palladium Catalyst. J. Chem. Soc., Chem. Commun.
1979, No. No. 19, 866.
(54) Down, K.; Amour, A.; Baldwin, I. R.; Cooper, A. W. J.; Deakin,
A. M.; Felton, L. M.; Guntrip, S. B.; Hardy, C.; Harrison, Z. A.; Jones,
K. L.; Jones, P.; Keeling, S. E.; Le, J.; Livia, S.; Lucas, F.; Lunniss, C. J.;
Parr, N. J.; Robinson, E.; Rowland, P.; Smith, S.; Thomas, D. A.;
Vitulli, G.; Washio, Y.; Hamblin, J. N. Optimization of Novel Indazoles
as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase
δ for the Treatment of Respiratory Disease. J. Med. Chem. 2015, 58
(18), 7381−7399.
(55) Dossetter, A. G.; Griffen, E. J.; Leach, A. G. Matched Molecular
Pair Analysis in Drug Discovery. Drug Discovery Today 2013, 18 (15−
16), 724−731.
(56) Ritchie, T. J.; Luscombe, C. N.; Macdonald, S. J. F. Analysis of
the Calculated Physicochemical Properties of Respiratory Drugs: Can
We Design for Inhaled Drugs Yet? J. Chem. Inf. Model. 2009, 49 (4),
1025−1032.
(57) Ball, J.; Archer, S.; Ward, S. PI3K Inhibitors as Potential
Therapeutics for Autoimmune Disease. Drug Discovery Today 2014, 19
(8), 1195−1199.
(58) Foster, J. G.; Blunt, M. D.; Carter, E.; Ward, S. G. Inhibition of
PI3K Signaling Spurs New Therapeutic Opportunities in Inflamma-
tory/Autoimmune Diseases and Hematological Malignancies. Pharma-
col. Rev. 2012, 64 (4), 1027−1054.
(59) Vanhaesebroeck, B.; Whitehead, M. A.; Piñeiro, R. Molecules in
Medicine Mini-Review: Isoforms of PI3K in Biology and Disease. J.
Mol. Med. 2016, 94 (1), 5−11.
(60) Taylor, R. D.; MacCoss, M.; Lawson, A. D. G. Rings in Drugs. J.
Med. Chem. 2014, 57 (14), 5845−5859.
(61) Goldberg, F. W.; Kettle, J. G.; Kogej, T.; Perry, M. W. D.;
Tomkinson, N. P. Designing Novel Building Blocks Is an Overlooked
Strategy to Improve Compound Quality. Drug Discovery Today 2015,
20 (1), 11−17.
(62) Bembenek, S. D.; Tounge, B. A.; Reynolds, C. H. Ligand
Efficiency and Fragment-Based Drug Discovery. Drug Discovery Today
2009, 14 (5−6), 278−283.
(63) Wang, A.; Dorso, C.; Kopcho, L.; Locke, G.; Langish, R.;
Harstad, E.; Shipkova, P.; Marcinkeviciene, J.; Hamann, L.; Kirby, M.
S. Potency, Selectivity and Prolonged Binding of Saxagliptin to DPP4:
Maintenance of DPP4 Inhibition by Saxagliptin in Vitro and Ex Vivo
When Compared to a Rapidly-Dissociating DPP4 Inhibitor. BMC
Pharmacol. 2012, 12 (1), 2.
(64) RCSB Protein Data Bank, http://www.rcsb.org/pdb/home/
home.do. April 18, 2014.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.6b01801
J. Med. Chem. 2017, 60, 1534−1554
1554
